Data / Research funding / Stimulant Use and Misuse
Stimulant Use and Misuse: 787 NIH awards ($1.2B) to 225 organizations
787 NIH awards ($1.2B) in the NIH spending category Stimulant Use and Misuse, to 225 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 787 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| NIDA Clinical Trials Network: Big South/West Node (CTN-0132 and CTN-0139) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $43,417,361 | March 1, 2025 | February 28, 2032 | TRIVEDI, MADHUKAR H. | reporter.nih.gov |
| The Florida Node Alliance of the National Drug Abuse Clinical Trials Network (CTN-121) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $26,301,696 | March 1, 2025 | February 29, 2028 | SZAPOCZNIK, JOSE | reporter.nih.gov |
| NorthStar Node of the NIDA Clinical Trials Network | NIH | National Institute on Drug Abuse | 2021 to 2025 | $22,374,119 | September 1, 2015 | February 29, 2032 | BART, GAVIN | reporter.nih.gov |
| The Ohio Valley Node of the Clinical Trials Network (CTN-0153) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $18,588,752 | March 1, 2025 | February 29, 2032 | WINHUSEN, T JOHN | reporter.nih.gov |
| Single cell transcriptomic and epigenomic changes during chronic HIV infection and cocaine self-administration | NIH | National Institute on Drug Abuse | 2022 to 2025 | $14,516,969 | June 1, 2022 | March 31, 2027 | ZENG, HONGKUI | reporter.nih.gov |
| OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2023 | $13,778,020 | September 30, 2021 | July 31, 2025 | STEVENS, MISTY WARD | reporter.nih.gov |
| Single Cell Transcriptomic and Epigenomic Dissection of Opioid and Cocaine Responses in HIV | NIH | National Institute on Drug Abuse | 2021 to 2025 | $12,564,620 | September 1, 2021 | June 30, 2027 | KELLIS, MANOLIS | reporter.nih.gov |
| AIDS Linked to the IntraVenous Experience (ALIVE) Study | NIH | National Institute on Drug Abuse | 2021 to 2025 | $12,226,379 | January 1, 2014 | May 31, 2030 | MEHTA, SHRUTI H | reporter.nih.gov |
| Clinical Development of a Therapeutic Agent for Rapid Reversal of Methamphetamine Intoxication | NIH | National Institute on Drug Abuse | 2023 to 2025 | $11,962,715 | August 15, 2023 | June 30, 2026 | LI, XINHUA | reporter.nih.gov |
| IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder | NIH | National Institute on Drug Abuse | 2022 to 2024 | $9,900,251 | September 30, 2022 | July 31, 2025 | STEVENS, MISTY WARD | reporter.nih.gov |
| M-SCORCH: Methamphetamine use disorder data generation center for Single Cell Opioid Responses in the Context of HIV | NIH | National Institute on Drug Abuse | 2021 to 2025 | $9,490,616 | May 15, 2021 | February 28, 2027 | HO, YA-CHI | reporter.nih.gov |
| Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder | NIH | National Institute on Drug Abuse | 2022 to 2024 | $8,683,509 | September 30, 2022 | July 31, 2025 | TOLL, LAWRENCE R | reporter.nih.gov |
| Development of a Long-acting Enzyme Therapy for Treatment of Cocaine Abuse | NIH | National Institute on Drug Abuse | 2021 to 2022 | $8,242,506 | August 15, 2020 | April 30, 2026 | ZHAN, CHANG-GUO | reporter.nih.gov |
| Therapeutic Agent for Rapid Reversal of Methamphetamine Intoxication | NIH | National Institute on Drug Abuse | 2021 to 2022 | $8,123,947 | September 30, 2020 | May 31, 2024 | LI, XINHUA | reporter.nih.gov |
| Greater Southern California Node of the Clinical Trials Network | NIH | National Institute on Drug Abuse | 2021 to 2025 | $7,788,993 | June 1, 2019 | February 29, 2032 | MOONEY, LARISSA JEANETTE | reporter.nih.gov |
| Single cell determinants of brain in the context of viral persistence in SIV/cART/cocaine non-human primates | NIH | National Institute on Drug Abuse | 2023 to 2025 | $7,434,979 | June 1, 2023 | February 29, 2028 | RANA, TARIQ M | reporter.nih.gov |
| Efficacy, safety, and pharmacokinetic study of BICX104 naltrexone subcutaneous implant alone and in combination with bupropion for the treatment of Methamphetamine Use Disorder (MUD). | NIH | National Institute on Drug Abuse | 2024 to 2025 | $7,405,564 | March 1, 2024 | November 30, 2027 | DEVARNEY, KATHERINE BEEBE | reporter.nih.gov |
| Cohort Studies of HIV/AIDS and Substance Use in Miami | NIH | National Institute on Drug Abuse | 2025 | $7,372,834 | September 30, 2025 | June 30, 2030 | BAUM, MARIANNA K | reporter.nih.gov |
| MSM and Substances Cohort at UCLA Linking Infections Noting Effects (MASCULINE) | NIH | National Institute on Drug Abuse | 2021 to 2024 | $7,177,379 | September 30, 2013 | April 30, 2026 | GORBACH, PAMINA MAE | reporter.nih.gov |
| Development of sigma receptor/DAT dual-targeting compounds to treat stimulant use disorder | NIH | National Institute on Drug Abuse | 2023 to 2024 | $6,903,733 | August 15, 2023 | July 31, 2026 | REICH, JEFFREY | reporter.nih.gov |
| Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism | NIH | National Institute on Drug Abuse | 2021 to 2024 | $6,868,774 | April 1, 2020 | January 31, 2026 | STRATHDEE, STEFFANIE A. | reporter.nih.gov |
| PDE7 Inhibitor for the Treatment of Cocaine Use Disorder | NIH | National Institute on Drug Abuse | 2023 to 2025 | $6,689,019 | April 15, 2023 | March 31, 2027 | GAITANARIS, GEORGE | reporter.nih.gov |
| Characterization, optimization, and development of dual mGlu2/3 positive allosteric modulators for opioid use disorder | NIH | National Institute on Drug Abuse | 2022 | $6,445,203 | July 15, 2022 | June 30, 2025 | COSFORD, NICHOLAS DAVID | reporter.nih.gov |
| Single Cell Transcriptomics of the Cocaine Use Disorder in the Context of HIV | NIH | National Institute on Drug Abuse | 2022 to 2025 | $6,266,450 | June 15, 2022 | March 31, 2027 | CHENG, CHRISTINE | reporter.nih.gov |
| Optimizing HIV prevention for high-risk methamphetamine-using men who have sex with men | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $5,855,396 | April 8, 2022 | April 30, 2027 | GROV, CHRISTIAN | reporter.nih.gov |
| Effects of HIV, Cocaine, and Prolonged ART Use on Subclinical Cardiovascular Disease | NIH | National Institute on Drug Abuse | 2021 to 2024 | $5,744,264 | June 1, 2016 | April 30, 2025 | LAI, SHENGHAN | reporter.nih.gov |
| Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $5,664,540 | March 1, 2025 | February 29, 2032 | HATCH, MARY AKIKO | reporter.nih.gov |
| Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS | NIH | National Institute on Drug Abuse | 2021 to 2022 | $5,613,312 | September 30, 2020 | June 30, 2024 | STEVENS, MISTY WARD | reporter.nih.gov |
| Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDS | NIH | National Institute on Drug Abuse | 2021 to 2024 | $5,321,290 | March 1, 2015 | April 30, 2026 | HAYASHI, KANNA | reporter.nih.gov |
| TMP-301, A Negative Allosteric Modulator of type 5 metabotropic glutamate receptors (mGluR5), for Treatment of Cocaine Use Disorder | NIH | National Institute on Drug Abuse | 2022 to 2023 | $5,310,920 | September 1, 2022 | August 31, 2025 | MEYERS, CHARLES DANIEL | reporter.nih.gov |
| Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization | NIH | National Institute on Drug Abuse | 2021 to 2022 | $5,281,643 | May 1, 2020 | February 29, 2024 | STEVENS, MISTY WARD | reporter.nih.gov |
| Development of TNX-1300 (Double Mutant Cocaine Esterase) for the Treatment of Life-Threatening Cocaine Intoxication | NIH | National Institute on Drug Abuse | 2022 to 2025 | $5,181,674 | August 1, 2022 | November 30, 2025 | SULLIVAN, GREGORY M | reporter.nih.gov |
| Modeling drugs of abuse-HIV interactions using iPSC-derived human cerebral organoids | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,890,555 | September 30, 2021 | July 31, 2026 | SANNA, PIETRO P | reporter.nih.gov |
| Single Chromatin Fiber Sequencing and Longitudinal Epigenomic Profiling in HIV+ Brain Cells Exposed to Narcotic and Stimulant | NIH | National Institute on Drug Abuse | 2022 to 2025 | $4,732,000 | April 1, 2022 | February 28, 2027 | AKBARIAN, SCHAHRAM | reporter.nih.gov |
| Single nucleus gene expression in moderate and compulsive drug self-administration in a rodent model of HIV | NIH | National Institute on Drug Abuse | 2022 to 2025 | $4,653,858 | March 15, 2022 | November 30, 2026 | SANNA, PIETRO P | reporter.nih.gov |
| Optimizing HIV prevention for highly vulnerable methamphetamine-using sexual minority men | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $4,518,889 | April 8, 2022 | April 30, 2024 | GROV, CHRISTIAN | reporter.nih.gov |
| Discovery of Addiction-Related Genes with Advanced Mouse Resources | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,405,786 | April 1, 2015 | May 31, 2027 | CHESLER, ELISSA J | reporter.nih.gov |
| Single nuclei transcriptome profiling in addiction circuitry of the HIV+ brain | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,310,228 | April 1, 2021 | February 28, 2027 | AKBARIAN, SCHAHRAM | reporter.nih.gov |
| Establishment and Characterization of Novel Mutant Mouse Models for the Addiction Research Community | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,218,988 | August 15, 2021 | May 31, 2027 | KUMAR, VIVEK | reporter.nih.gov |
| Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2024 | $4,182,561 | May 1, 2024 | August 31, 2025 | ESBENSEN, ANNA J. | reporter.nih.gov |
| Identification of Genetic Variants that Contribute to Compulsive Cocaine Intakein Rats | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,976,898 | April 1, 2017 | June 30, 2027 | GEORGE, OLIVIER | reporter.nih.gov |
| Early Life Stress, Chronic Drug Use and Neuroplasticity in Nonhuman Primate Models of Cocaine Abuse: Relevance to Treatment Strategies | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,974,079 | April 1, 2021 | January 31, 2027 | SANCHEZ, MAR M | reporter.nih.gov |
| Making Better Decisions: Policy Modeling for AIDS and Drug Abuse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,865,844 | September 25, 2022 | January 31, 2029 | OWENS, DOUGLAS K | reporter.nih.gov |
| Spatio-temporal Methods for Surveillance of the Opioid Syndemic | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,748,657 | September 1, 2025 | August 31, 2029 | KLINE, DAVID M | reporter.nih.gov |
| The Comparative Effectiveness and Safety of Pharmacotherapies for the Treatment of Opioid Use Disorder in Pregnancy | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,680,536 | April 1, 2020 | May 31, 2029 | HUYBRECHTS, KRISTA F | reporter.nih.gov |
| Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,677,031 | August 20, 2021 | May 31, 2027 | KAWUT, STEVEN M | reporter.nih.gov |
| Understanding neuronal subtype-specific function of NAc in cocaine addiction | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,661,419 | April 1, 2021 | February 28, 2026 | ZHANG, YI | reporter.nih.gov |
| Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C UCB J PET Study | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,657,020 | July 1, 2021 | April 30, 2027 | ANGARITA, GUSTAVO ADOLFO | reporter.nih.gov |
| Structure and Function of Dopamine Receptors | NIH | National Institute of Mental Health | 2021 to 2025 | $3,613,300 | September 1, 1995 | April 30, 2027 | JAVITCH, JONATHAN A | reporter.nih.gov |
| Small molecule modulators of ΔFosB | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,586,553 | July 1, 2016 | March 31, 2027 | RUDENKO, GABRIELLE | reporter.nih.gov |
| PTPRD Phosphatase inhibitors for stimulant use disorders | NIH | National Institute on Drug Abuse | 2022 to 2024 | $3,540,141 | July 1, 2022 | June 30, 2025 | UHL, GEORGE RICHARD | reporter.nih.gov |
| Synthetics in Combination (SYNC) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,536,582 | September 30, 2021 | June 30, 2026 | CICCARONE, DANIEL H | reporter.nih.gov |
| Allosteric Modulators of Dopamine Transporter as Therapeutic Agents for NeuroAIDS | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,446,099 | July 1, 2020 | April 30, 2026 | AUGELLI-SZAFRAN, CORINNE ELIZABETH | reporter.nih.gov |
| Peer-Delivered, Behavioral Activation Intervention to Improve Polysubstance Use and Retention in Mobile Telemedicine OUD Treatment in an Underserved, Rural Area | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,434,019 | September 30, 2022 | August 31, 2027 | MAGIDSON, JESSICA F | reporter.nih.gov |
| Secondhand Harms from Alcohol & Drugs: Impacts on Families and Communities across the US | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $3,368,295 | September 20, 2021 | June 30, 2027 | KERR, WILLIAM C. | reporter.nih.gov |
| Epigenetic mechanisms of sustained transcription across cocaine abstinence | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,351,544 | July 1, 2021 | May 31, 2026 | HELLER, ELIZABETH A | reporter.nih.gov |
| Promoting remote and secondary risk prevention services in rural settings | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,349,340 | September 30, 2022 | July 31, 2027 | PHO, MAI TUYET | reporter.nih.gov |
| Drug development of clavulanic acid, a GLT-1 activator: proof of concept for cocaine use disorder | NIH | National Institute on Drug Abuse | 2022 to 2023 | $3,340,215 | May 15, 2020 | December 31, 2024 | MORRISON, MARY F. | reporter.nih.gov |
| Project Nurture Expansion Study | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,304,098 | September 24, 2021 | August 31, 2026 | COHEN, DEBORAH JILL | reporter.nih.gov |
| IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorder | NIH | National Institute on Drug Abuse | 2025 | $3,287,052 | May 15, 2025 | April 30, 2027 | SHIRLEY, RENEE LYNN | reporter.nih.gov |
| PRIME: PrEP Intervention for people who Inject MEthamphetamine | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,225,418 | August 1, 2020 | June 30, 2026 | COFFIN, PHILLIP O | reporter.nih.gov |
| Neurocognitive Abnormalities in Stimulant Abuse among High-Risk Women | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,207,045 | August 1, 2022 | May 31, 2027 | KIEHL, KENT A | reporter.nih.gov |
| Genetics of novelty seeking and propensity for drug abuse in outbred rats | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,193,903 | September 1, 2023 | June 30, 2028 | AKIL, HUDA | reporter.nih.gov |
| Cocaine use, viral suppression and precursors of stroke in HIV infection | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,185,105 | June 1, 2020 | April 30, 2026 | RILEY, ELISE D. | reporter.nih.gov |
| Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse | NIH | National Institute on Drug Abuse | 2021 to 2023 | $3,182,913 | September 30, 2021 | August 31, 2024 | YOUNG, ERICA J | reporter.nih.gov |
| A DUAL CHIMERIC HUMAN ASTROGLIAL-MICROGLIAL MODEL OF HIV AND HAND | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,125,946 | August 1, 2021 | May 31, 2026 | GOLDMAN, STEVEN ALAN | reporter.nih.gov |
| Contingency management plus deep transcranial magnetic stimulation for the treatment of cocaine use disorder | NIH | National Institute on Drug Abuse | 2025 | $3,119,619 | September 15, 2025 | June 30, 2029 | SCHMITZ, JOY MARIE | reporter.nih.gov |
| Preferences and predictors driving opioid-involved polysubstance use profiles and trajectories: Implications for improving care | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,119,296 | September 30, 2022 | August 31, 2027 | COUGHLIN, LARA NICOLE | reporter.nih.gov |
| PET Imaging of neurochemical transmission in cocaine use disorders | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,096,100 | September 30, 2009 | June 30, 2027 | NARENDRAN, RAJESH | reporter.nih.gov |
| Mechanisms Mediating Cocaine Abuse in Socially Housed Female and Male Monkeys | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,072,958 | September 1, 2001 | May 31, 2029 | NADER, MICHAEL A | reporter.nih.gov |
| cART, neuroHIV, cocaine abuse and the mPFC neuron/astrocyte dysfunction | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,070,264 | September 15, 2022 | August 31, 2027 | HU, XIU-TI | reporter.nih.gov |
| The short and long-term dynamics of opioid/stimulant use: Mixed methods to inform overdose prevention and treatment related to polysubstance use | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,051,259 | September 30, 2022 | July 31, 2027 | GENBERG, BECKY LYNN | reporter.nih.gov |
| Treating Polysubstance Use in Methadone Maintenance: Application of Novel Digital Technology | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,027,776 | September 30, 2022 | July 31, 2027 | ALEXANDER, KAREN | reporter.nih.gov |
| Atherosclerosis in cocaine addiction: imaging risk with PET/MR | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,015,410 | June 1, 2022 | March 31, 2027 | ALIA-KLEIN, NELLY | reporter.nih.gov |
| AIM(2)ing at the inflammasome: Impact of MAVS signaling in cocaine-and HIV-1 induced neuroinflammation | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,004,104 | March 15, 2021 | February 28, 2027 | CISNEROS, IRMA | reporter.nih.gov |
| Disrupting Social Risk Factors of Health to Improve Substance Use and Mental Health Outcomes for Parents in Rural Regions | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,001,349 | September 1, 2023 | August 31, 2027 | SALDANA, LISA | reporter.nih.gov |
| reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA) | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,978,902 | September 1, 2022 | July 31, 2028 | SZAPOCZNIK, JOSE | reporter.nih.gov |
| Molecular Studies of Cocaine Action in Brain | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,971,622 | August 1, 1991 | January 31, 2026 | NESTLER, ERIC J. | reporter.nih.gov |
| Role of GRIN2 in ART and SUD associated neurological deficits. | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,965,829 | September 15, 2022 | August 31, 2027 | DASH, CHANDRAVANU | reporter.nih.gov |
| The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR) | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,923,597 | July 1, 2023 | June 30, 2025 | NWAOKOBIA, CHARLES CHIEDU | reporter.nih.gov |
| Opioid and SUD Data Enclave (O-SUDDEn): Bringing real-time data to the opioid crisis | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,921,106 | September 30, 2022 | August 31, 2027 | FERNANDEZ, SOLEDAD A | reporter.nih.gov |
| D1 and D2 Dopaminoceptive Ensembles in Limbic Brain Regions in Drug Addiction | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,909,999 | September 1, 2000 | April 30, 2030 | NESTLER, ERIC J. | reporter.nih.gov |
| Assessing the Reach, Effectiveness, and Implementation of Multiple Interventions | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,900,711 | September 30, 2022 | July 31, 2027 | KRAL, ALEXANDER H | reporter.nih.gov |
| COINSTAC 2.0: decentralized, scalable analysis of loosely coupled data | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,856,703 | July 1, 2015 | June 30, 2026 | CALHOUN, VINCE D | reporter.nih.gov |
| Reelin Signaling and Function in Cocaine Response | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,847,900 | July 1, 2021 | April 30, 2027 | DAY, JEREMY J | reporter.nih.gov |
| The Role of the Dopamine Transporter in Psychostimulant Abuse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,835,033 | July 1, 2014 | November 30, 2026 | GALLI, AURELIO | reporter.nih.gov |
| Integrated Safety Optimization Services for People Who Use Drugs In Targeted Areas Of High Overdose Rates | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,833,774 | September 30, 2022 | August 31, 2027 | JORDAN, AYANA | reporter.nih.gov |
| An Experimental Medicine Approach for the Mechanistic Understanding of Cocaine Use Disorder: Reinforcer Pathology | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,821,784 | July 15, 2022 | April 30, 2027 | LACONTE, STEPHEN M | reporter.nih.gov |
| In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,820,000 | June 1, 2022 | May 31, 2026 | PIPPIN, DOUGLAS ANTHONY | reporter.nih.gov |
| Exploring Influences on Methamphetamine Use Among Males in Georgia | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,785,741 | June 1, 2022 | March 31, 2027 | HUSSEN, SOPHIA A. | reporter.nih.gov |
| Drug abuse and HIV-associated pulmonary vascular injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,784,947 | February 1, 2021 | December 31, 2025 | DHILLON, NAVNEET KAUR | reporter.nih.gov |
| Gene Network Identification and Integration (GNetii) Approach to Understanding the Biology Underlying HIV and Drug Abuse. | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,762,265 | August 1, 2020 | May 31, 2026 | JOHNSON, ERIC OTTO | reporter.nih.gov |
| Sex differences in the neural correlates underlying impairments in response inhibition and salience attribution in cocaine addiction | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,749,037 | April 1, 2020 | February 28, 2025 | GOLDSTEIN, RITA Z | reporter.nih.gov |
| Peer Engagement in Methamphetamine Harm-Reduction with Contingency Management (PEER-CM) | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,732,822 | September 30, 2022 | July 31, 2027 | KORTHUIS, PHILIP TODD | reporter.nih.gov |
| Altered Midbrain GABAergic Circuitry Drives Greater Cocaine Self-administration | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,670,057 | May 15, 2021 | February 28, 2026 | DANI, JOHN A. | reporter.nih.gov |
| A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness (Administrative supplement) | NIH | National Institute on Drug Abuse | 2022 to 2023 | $2,661,063 | November 1, 2023 | September 29, 2025 | MCNEIL, RYAN | reporter.nih.gov |
| Epigenetic mechanisms in the medial habenula governing drug-seeking behavior | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,638,720 | July 15, 2020 | April 30, 2026 | WOOD, MARCELO ANDRES | reporter.nih.gov |
| Leveraging data synthesis to identify optimal and robust strategies for HIV elimination among substance-using MSM | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,637,647 | May 1, 2022 | February 28, 2027 | JANULIS, PATRICK FRANCIS | reporter.nih.gov |
| Cocaine-induced mitochondrial mechanisms and molecular mediators in reward circuitry | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,612,514 | September 15, 2014 | June 30, 2027 | LOBO, MARY KAY | reporter.nih.gov |
| Varieties of Impulsivity in Opiate and Stimulant Users | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,598,683 | July 15, 2008 | May 31, 2027 | VASSILEVA, JASMIN L | reporter.nih.gov |
| Role of Gadd45b in Cocaine-driven Epigenetic and Behavioral Dynamics | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,581,972 | May 1, 2022 | March 31, 2027 | DAY, JEREMY J | reporter.nih.gov |
| Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,568,075 | May 1, 2020 | January 31, 2026 | MOELLER, FREDERICK GERARD | reporter.nih.gov |
| A Clinical Laboratory with Integrated Neuroscience (CLIN) for Early Evaluation of Medications for Substance Use Disorders | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,557,655 | May 1, 2020 | January 31, 2026 | KAMPMAN, KYLE MATTHEW | reporter.nih.gov |
| Examining the Skeletal Effects of Psychostimulants | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,545,386 | August 20, 2020 | June 30, 2026 | CALARGE, CHADI A. | reporter.nih.gov |
| Cross platform analysis of drug targets and toxicity of bath salts | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,538,810 | September 15, 2022 | June 30, 2027 | SCHIEFER, ISAAC T | reporter.nih.gov |
| Methamphetamine Effect on HIV Persistence | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,535,677 | July 1, 2020 | May 31, 2025 | KAUL, MARCUS | reporter.nih.gov |
| Kappa Opioid Receptors and Phospho-Dopamine Transporters Drive Cocaine Reward | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,532,199 | September 15, 2022 | June 30, 2027 | RAMAMOORTHY, SAMMANDA | reporter.nih.gov |
| Novel Therapeutic Agents to Reverse Opioid Overdose | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,529,335 | September 30, 2020 | August 31, 2025 | LI, XINHUA | reporter.nih.gov |
| CASCADE: A North Carolina cohort to address the cascading effects of the HIV and substance use syndemic | NIH | National Institute on Drug Abuse | 2025 | $2,528,513 | September 1, 2025 | July 31, 2030 | MEADE, CHRISTINA S | reporter.nih.gov |
| Genomic profiling mediating the protective effect of social reward on opioid craving | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,512,064 | August 1, 2022 | June 30, 2027 | VENNIRO, MARCO | reporter.nih.gov |
| HIV, Methamphetamine and Human iPSC-derived Microglia-containing Cerebral Organoids | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,470,488 | July 1, 2020 | April 30, 2026 | HO, WENZHE | reporter.nih.gov |
| Genetics of Cocaine Sensitivity in Drosophila | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,469,830 | September 15, 2017 | April 30, 2027 | MACKAY, TRUDY F. | reporter.nih.gov |
| Taking Our Shot: Extended-Release Naltrexone as Opioid Overdose Pre-Exposure Prophylaxis (PrEP) in People Using Stimulants Living With or At Risk of HIV | NIH | National Institute on Drug Abuse | 2024 | $2,460,000 | July 1, 2024 | June 30, 2028 | APPA, AYESHA A | reporter.nih.gov |
| Novel Dopaminergic Stimulant Prodrug for the Treatment of Apathy in AD | NIH | National Institute on Aging | 2021 to 2022 | $2,458,641 | July 1, 2022 | March 31, 2024 | PATIL, SANDEEP | reporter.nih.gov |
| Parvalbumin interneurons regulate nucleus accumbens synapses and behavior | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,435,138 | September 1, 2016 | May 31, 2026 | GRUETER, BRAD ALAN | reporter.nih.gov |
| MEDICATION DISCOVERY USING RAT MODELS OF RELAPSE. PERIOD OF PERFORMANCE: 7/10/2019-7/9/2024. N01DA-19-8949 | NIH | National Institute on Drug Abuse | 2022 to 2023 | $2,430,107 | July 10, 2019 | July 9, 2024 | SHELTON, KEITH | reporter.nih.gov |
| Mechanisms of dopaminergic dysfunction in substance use disorder | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,425,095 | September 30, 2021 | July 31, 2026 | CALIPARI, ERIN | reporter.nih.gov |
| Breaking bonds in prairie voles | NIH | National Institute of Mental Health | 2022 to 2025 | $2,413,644 | March 1, 2022 | December 31, 2026 | KABBAJ, MOHAMED | reporter.nih.gov |
| Modeling HIV and methamphetamine-induced neuroinflammation in cerebral organoids | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,395,254 | September 1, 2022 | July 31, 2027 | SPEARMAN, PAUL W. | reporter.nih.gov |
| New targeted BDNF nanoparticles for treatment of METH addiction and neurotoxicity | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,378,918 | September 1, 2021 | August 31, 2025 | VITALIANO, FRANCO | reporter.nih.gov |
| Methamphetamine and Other Substance Use Disorder Genetics in Thailand | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,375,708 | June 15, 2015 | April 30, 2028 | GELERNTER, JOEL | reporter.nih.gov |
| Regulation of HIV latency by microglial-neuronal interactions | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,363,459 | September 15, 2019 | July 31, 2025 | KARN, JONATHAN | reporter.nih.gov |
| Investigating the molecular mechanisms of HIV/AIDS associated neurological disorders using microglia and cerebral organoids derived from induced pluripotent stem cells | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,348,133 | September 1, 2019 | July 31, 2025 | RANA, TARIQ M | reporter.nih.gov |
| Examining the Impact of the Twin Epidemics of Methamphetamine and Opioid Use on Overdose, Risky Sex and Treatment Engagement among PWUD in Two Rural Appalachian Cohorts | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,345,140 | September 1, 2012 | March 31, 2028 | HAVENS, JENNIFER R | reporter.nih.gov |
| In Vivo Imaging and Post-Mortem Study of Methamphetamine Use on Immune Dysfunction and HIV Reservoir Transcription among People with HIV on ART | NIH | National Institute on Drug Abuse | 2025 | $2,331,737 | July 15, 2025 | May 31, 2030 | HENRICH, TIMOTHY JENSEN | reporter.nih.gov |
| Neighborhood conditions, neural circuits, and substance use behaviors across the early life course. | NIH | National Institute on Drug Abuse | 2025 | $2,314,254 | September 30, 2025 | June 30, 2029 | BARR, PETER BRENDAN | reporter.nih.gov |
| Unraveling the intersection of substance use, inflammation, and HIV via hair levels | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,283,571 | July 1, 2023 | May 31, 2028 | GANDHI, MONICA | reporter.nih.gov |
| Computational modeling to evaluate interventions for HIV and substance use | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,266,145 | September 30, 2023 | July 31, 2028 | HOTTON, ANNA | reporter.nih.gov |
| Impact of prescription stimulants on the drug overdose epidemic | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,253,245 | May 1, 2023 | March 31, 2028 | DE NADAI, ALESSANDRO STEVENS | reporter.nih.gov |
| The Rhode Island Young Adult Prescription and Illicit Drug Study (RAPIDS): Responding to Fentanyl and Associated Harms | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,243,163 | August 15, 2019 | May 31, 2025 | MARSHALL, BRANDON DAVID LEWIS | reporter.nih.gov |
| Synthetic Psychoactive "Bath Salt" Effects on Brain Activity and Behavior | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,232,449 | April 15, 2019 | February 28, 2025 | KOHUT, STEPHEN JOHN | reporter.nih.gov |
| Autophagic regulation of cocaine abuse | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,222,317 | August 15, 2022 | May 31, 2027 | HE, CONGCONG | reporter.nih.gov |
| Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuse and Aging on Cognitive Impairment | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,208,551 | July 15, 2020 | May 2, 2024 | NIXON, DOUGLAS F | reporter.nih.gov |
| Ghrelin Deacylase as a Treatment for Opioid Polysubstance Abuse | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,207,625 | July 1, 2022 | June 30, 2027 | ZHAN, CHANG-GUO | reporter.nih.gov |
| Glial-mediated synaptic remodeling in drug addiction | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,202,322 | June 1, 2016 | April 30, 2027 | DONG, YAN | reporter.nih.gov |
| Assessment of metformin for restoration of immune homeostasis in HIV+ and HIV- individuals with a history of injection drug use | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,193,459 | September 30, 2024 | May 31, 2029 | KOBIE, JAMES J | reporter.nih.gov |
| Circadian Rhythms and Cocaine Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,173,145 | August 1, 2021 | May 31, 2026 | FERRIS, MARK J | reporter.nih.gov |
| High-throughput Identification of Non-hallucinogenic Psychoplastogens for Treating Addiction | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,172,679 | May 15, 2022 | February 28, 2027 | OLSON, DAVID E | reporter.nih.gov |
| Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memory | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,164,851 | December 15, 2019 | November 30, 2025 | MILLER, COURTNEY A | reporter.nih.gov |
| The Dopamine Synapse and Associative Learning | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,161,538 | July 1, 1991 | December 31, 2028 | SULZER, DAVID | reporter.nih.gov |
| Investigate Host Gene Isoforms Contributing to HIV Persistence in Cocaine Users | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,161,166 | September 30, 2023 | July 31, 2028 | ZHU, JIAN | reporter.nih.gov |
| Cocaine, Parvalbumin, and Perineuronal Nets | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,155,184 | April 1, 2023 | January 31, 2028 | SORG, BARBARA A | reporter.nih.gov |
| 5-HT2 Receptor Allosterism in Cocaine Use Disorder | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,154,204 | August 1, 2015 | April 30, 2027 | ZHOU, JIA | reporter.nih.gov |
| Optimizing PrEP adherence in sexual minority men who use stimulants | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,152,006 | July 1, 2020 | July 3, 2023 | CARRICO, ADAM WAYNE | reporter.nih.gov |
| Human/Animal Brain Chimera in drugs of abuse and HIV | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,144,306 | August 15, 2022 | May 31, 2027 | AL-HARTHI, LENA | reporter.nih.gov |
| Cocaine-induced adaptation in NMDA receptors | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,139,400 | December 1, 2022 | November 30, 2027 | DONG, YAN | reporter.nih.gov |
| 1/2 Treating Mothers with ADHD and their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation Trial | NIH | National Institute of Mental Health | 2021 to 2023 | $2,137,454 | August 7, 2019 | July 31, 2024 | STEIN, MARK A | reporter.nih.gov |
| Comorbidities and other consequences at the intersection of the HIV and substance use epidemics | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,110,949 | September 1, 2023 | June 30, 2028 | CRANE, HEIDI M. | reporter.nih.gov |
| Effectiveness and Outcomes of Combined Contingency Management and CBT for Alcohol Use Disorder | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $2,107,134 | June 1, 2019 | May 31, 2025 | DEDERT, ERIC A | reporter.nih.gov |
| Inflammasome activation in an SIV-ART model of chronic drug abuse | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,104,458 | September 30, 2019 | July 31, 2025 | VEENHUIS, REBECCA TERILLI | reporter.nih.gov |
| Individual Differences & Cocaine Effects on Impulsive Choice in Rat | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,102,499 | July 1, 2016 | March 31, 2027 | TAYLOR, JANE R | reporter.nih.gov |
| Stimulant-induced excitatory and inhibitory dopamine receptor signaling and trafficking | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,098,117 | September 30, 2023 | June 30, 2028 | SANDER, CHRISTIN Y. | reporter.nih.gov |
| Cerebral organoid and IPSC derived microglia: Modeling of HIV and methamphetamine co-morbidity | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,096,889 | September 1, 2022 | July 31, 2027 | YELAMANCHILI, SOWMYA | reporter.nih.gov |
| Immune mechanisms that shape the blood brain barrier in people living with HIV and cocaine use disorder | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,096,862 | June 1, 2024 | March 31, 2029 | VEENHUIS, REBECCA TERILLI | reporter.nih.gov |
| Decentralized clinical trial of contingency management digital therapeutic to treat stimulant use disorder | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,087,604 | September 15, 2024 | August 31, 2027 | GASTFRIEND, DAVID R | reporter.nih.gov |
| Risk Factors for Psychosis and Mania with Prescription Amphetamine Use | NIH | National Institute of Mental Health | 2021 to 2023 | $2,082,432 | June 10, 2020 | April 30, 2025 | SHINN, ANN KYUNGAH | reporter.nih.gov |
| Benzodiazepine Choice and Polydrug Use | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,074,200 | April 1, 2022 | January 31, 2027 | HUSKINSON, SALLY L | reporter.nih.gov |
| Neuroimmune pathways linking chronic psychosocial stress to co-occurring stimulant use and depression in HIV disease: a mechanistic clinical trial | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,071,030 | September 1, 2024 | May 31, 2029 | MEADE, CHRISTINA S | reporter.nih.gov |
| New psychoactive substance exposure among NYC nightclub and festival attendees | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,051,804 | August 15, 2023 | May 31, 2027 | PALAMAR, JOSEPH J | reporter.nih.gov |
| Influence of Orexin Antagonism on Opioid and Methamphetamine Demand | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,047,388 | April 15, 2023 | December 1, 2025 | STRICKLAND, JUSTIN CHARLES | reporter.nih.gov |
| Dopaminergic and Glutamatergic Mechanisms of Cocaine Addiction: Sex Differences | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,046,903 | April 1, 2008 | May 31, 2027 | LYNCH, WENDY JEAN | reporter.nih.gov |
| Targeting gut brain-signaling to reduce cocaine seeking behaviors | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,040,985 | September 1, 2023 | June 30, 2028 | KIRALY, DREW | reporter.nih.gov |
| Supporting data-driven decision-making to support substance use service expansion policies and to prevent overdoses | NIH | National Institute on Drug Abuse | 2024 to 2025 | $2,033,987 | September 1, 2023 | August 31, 2028 | CRUDEN, GRACELYN | reporter.nih.gov |
| Retinoic acid, homeostatic plasticity and cocaine craving | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,026,004 | March 15, 2020 | December 31, 2025 | WOLF, MARINA ELIZABETH | reporter.nih.gov |
| Developing a U.S. National Cohort to Improve Virologic Suppression among Stimulant-using Men Living with HIV. | NIH | National Institute on Drug Abuse | 2023 to 2024 | $2,024,874 | May 15, 2023 | April 30, 2025 | SPINELLI, MATTHEW A. | reporter.nih.gov |
| Glutamate receptor plasticity underlying incubation of methamphetamine craving | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,013,645 | September 1, 1996 | March 31, 2028 | WOLF, MARINA ELIZABETH | reporter.nih.gov |
| Uptake2 transporters: Novel sex-dependent molecular targets to treat stimulant use disorder | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,011,549 | July 15, 2023 | May 31, 2028 | DAWS, LYNETTE C | reporter.nih.gov |
| Neural mechanisms regulating cocaine consumption | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,000,599 | July 15, 2020 | April 30, 2026 | PHILLIPS, PAUL E. M. | reporter.nih.gov |
| Mitochondrial signaling dynamics in cocaine use disorder | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,977,342 | August 15, 2023 | June 30, 2028 | ABRAHAM, ANTONY DANIEL | reporter.nih.gov |
| X chromosome inactivation in sex disparities to substance use disorder | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,974,500 | August 15, 2021 | May 31, 2027 | OGHUMU, STEVE ONYEKA | reporter.nih.gov |
| Stimulant and Polysubstance use, Inflammation and Sex Effects on Myocardial Disease in HIV (SPISE) | NIH | National Institute on Drug Abuse | 2025 | $1,969,877 | July 15, 2025 | March 31, 2030 | TIEN, PHYLLIS C | reporter.nih.gov |
| Integration of Peer Navigation and mHealth Technology to Improve Viral Suppression among Racial and Ethnic Minority PLWH in Community-Based HIV Care Clinics | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,963,075 | September 30, 2020 | July 31, 2025 | PITPITAN, EILEEN VIRTUSIO | reporter.nih.gov |
| The Role of the Bed Nucleus of the Stria Terminalis-Norepinephrine System in Amphetamine-type Stimulant Use Disorders | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,958,010 | September 15, 2023 | June 30, 2028 | PARK, JINWOO | reporter.nih.gov |
| Novel Addiction Neurocircuits in Cocaine Taking | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,955,360 | April 1, 2022 | January 31, 2027 | HOMMEL, JONATHAN DEAN | reporter.nih.gov |
| Effects of HIV-1 Tat protein and methamphetamine on VMAT2-mediated dopamine transmission in the context of neuroHIV and drug abuse | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,939,156 | April 1, 2023 | April 30, 2025 | ZHU, JUN | reporter.nih.gov |
| Examining predictors of substance use and treatment adequacy among formerly incarcerated opiod and cocaine users | NIH | National Institute on Drug Abuse | 2022 to 2024 | $1,937,137 | August 1, 2022 | June 30, 2027 | ROWELL-CUNSOLO, TAWANDRA LASHONE | reporter.nih.gov |
| Regulation of striatal microcircuits by endogenous opioids as a novel mechanism underlying cocaine seeking | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,936,984 | August 1, 2022 | May 31, 2027 | DOBBS, LAUREN K | reporter.nih.gov |
| Relationship between methamphetamine use, viral reservoir dynamics and clinical progression in treated HIV infection | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,936,729 | June 1, 2023 | April 30, 2028 | STEVENSON, MARIO | reporter.nih.gov |
| Cocaine: effects on single neurons | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,925,000 | July 1, 1987 | July 31, 2027 | WILLIAMS, JOHN T | reporter.nih.gov |
| SARS-CoV-2 signaling and interactions with stimulant drugs of abuse via Sigma-1R: Impact on the BBB | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,914,927 | July 1, 2022 | April 30, 2027 | UNTERWALD, ELLEN M | reporter.nih.gov |
| Methamphetamine, mitochondria, and neurodegeneration | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,908,298 | April 15, 2021 | January 31, 2027 | GRAVES, STEVEN MICHAEL | reporter.nih.gov |
| Determinants of Drug Preference in Humans | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,905,360 | January 1, 1981 | January 31, 2026 | DE WIT, HARRIET | reporter.nih.gov |
| Molecular mechanisms underlying HIV & Cocaine-mediated microglial activation: Targeting NLRP3 inflammasome | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,904,596 | September 30, 2019 | July 31, 2025 | BUCH, SHILPA J. | reporter.nih.gov |
| Methamphetamine Effects on Prefrontal Cortical PV+ Interneurons and Resulting Cognitive Deficits | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,891,855 | September 1, 2021 | July 31, 2026 | LAVIN, ANTONIETA | reporter.nih.gov |
| Development and validation of a novel point-of-care technology for rapid non-targeted identification of emerging opioid and other drug threats | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,866,922 | September 30, 2023 | August 31, 2027 | WERB, DANIEL M | reporter.nih.gov |
| Pioglitazone as an adjunct to CBT for cocaine relapse prevention | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,864,756 | July 1, 2020 | May 31, 2025 | SCHMITZ, JOY MARIE | reporter.nih.gov |
| Optimizing PrEP adherence in sexual minority men who use stimulants | NIH | National Institute on Drug Abuse | 2023 to 2024 | $1,855,864 | July 1, 2020 | May 31, 2025 | CARRICO, ADAM WAYNE | reporter.nih.gov |
| Glutamergic Mechanisms in Opioid and Cocaine Co-Use | NIH | National Institute on Drug Abuse | 2022 to 2024 | $1,854,763 | September 30, 2020 | August 31, 2025 | GIPSON-REICHARDT, CASSANDRA D | reporter.nih.gov |
| Screen, Treat and Retain People with Primary Meth Use Disorder at MMT Clinics (STAR-OM+) | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,829,872 | May 1, 2024 | March 31, 2025 | LE, GIANG M | reporter.nih.gov |
| Developing a U.S. National Cohort to Improve Virologic Suppression among Stimulant-using Men Living with HIV. | NIH | National Institute on Drug Abuse | 2025 | $1,828,735 | May 15, 2023 | April 30, 2028 | SPINELLI, MATTHEW A. | reporter.nih.gov |
| The role of RGS12 in differential modulation of G protein versus beta-arrestin signaling downstream of the kappa opioid receptor | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,819,514 | February 15, 2021 | December 31, 2025 | SIDEROVSKI, DAVID P. | reporter.nih.gov |
| Structure and Function of Neurotransmitter Transporters | NIH | National Institute of Mental Health | 2025 | $1,810,118 | July 1, 2004 | May 31, 2029 | GOUAUX, JAMES E | reporter.nih.gov |
| Incubated drug-craving and neurochemical interactions | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,780,211 | April 15, 2021 | December 31, 2025 | SZUMLINSKI, KAREN KATHLEEN | reporter.nih.gov |
| Mining Social Media Big Data for Toxicovigilance: Studying Substance Use via Natural Language Processing and Machine Learning Methods | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,773,166 | September 30, 2022 | July 31, 2027 | SARKER, ABEED H | reporter.nih.gov |
| Neural systems mediating the extinction and inhibition of cocaine seeking | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,771,684 | July 15, 2020 | April 30, 2026 | LALUMIERE, RYAN T | reporter.nih.gov |
| Mechanisms underlying the influence of stress on drug-seeking behavior | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,764,926 | July 1, 2023 | April 30, 2028 | MANTSCH, JOHN R | reporter.nih.gov |
| Systems biology of RNA Modifications in HIV/AIDS and Substance Use Disorders | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,760,840 | March 15, 2018 | December 31, 2023 | SANNA, PIETRO P | reporter.nih.gov |
| Rapid and non-invasive device for drug detection through sweat | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,738,402 | September 30, 2020 | July 31, 2025 | KULKARNI, GIRISH | reporter.nih.gov |
| Calcium-related neurotoxicity of cocaine | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,729,326 | February 15, 2012 | January 31, 2027 | DU, CONGWU | reporter.nih.gov |
| Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,726,798 | July 1, 2013 | April 30, 2025 | ZHU, JUN | reporter.nih.gov |
| Hippocampal mechanisms of cocaine-memory reconsolidation | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,719,615 | June 1, 2023 | March 30, 2028 | FUCHS LOKENSGARD, RITA A | reporter.nih.gov |
| Methamphetamine injection, associated health risk, and causes of overdose deaths. | NIH | National Institute on Drug Abuse | 2022 to 2024 | $1,714,422 | September 30, 2022 | July 31, 2025 | KRAL, ALEXANDER H | reporter.nih.gov |
| PACAP-Dependent Coordination of Glutamate Signaling between Neurons and Astrocytes | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,708,450 | August 15, 2020 | April 30, 2027 | BAKER, DAVID A | reporter.nih.gov |
| Short-term and long-term effects of methamphetamine exposure on residual viral transcription during treated HIV disease | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,702,671 | August 1, 2018 | May 31, 2026 | LEE, SULGGI ANGELA | reporter.nih.gov |
| Nitrergic interneurons and cue-induced cocaine seeking | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,697,532 | August 1, 2021 | May 31, 2027 | SCOFIELD, MICHAEL DAVID | reporter.nih.gov |
| Genetic and hormonal contributions to sex differences in vulnerability to drug use | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,691,545 | March 1, 2020 | December 31, 2025 | LYNCH, WENDY JEAN | reporter.nih.gov |
| Nature and Predictors of Impaired Harm Avoidance in Polysubstance Abuse | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,690,491 | July 1, 2018 | June 30, 2026 | OTTO, MICHAEL W. | reporter.nih.gov |
| Translational Research Training in Addictions: Pathways for Behavioral and Biomedical Scholars (TRACC). | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,690,151 | June 15, 2013 | June 30, 2030 | RUGLASS, LESIA MONIQUE | reporter.nih.gov |
| Regulation of Dopamine Transporter by Trafficking | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,683,175 | April 1, 2001 | June 30, 2028 | SORKIN, ALEXANDER D | reporter.nih.gov |
| The impact of methamphetamine on CXCL12 mediated HIV neuropathogenesis | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,680,000 | July 15, 2022 | May 31, 2027 | BERMAN, JOAN WEINBERGER | reporter.nih.gov |
| Diurnal rhythms in the nucleus accumbens: Mechanisms and role in substance use disorders | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,678,144 | July 1, 2015 | March 31, 2026 | MCCLUNG, COLLEEN A | reporter.nih.gov |
| Host and viral genomic determinants of HIV latent reservoir size and characteristics in individuals with substance use disorders | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,677,906 | August 15, 2018 | May 31, 2024 | SILICIANO, ROBERT F | reporter.nih.gov |
| Cognitive Reappraisal for Mitigating Incubation of Cocaine Cue-Reactivity | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,675,624 | September 30, 2023 | August 31, 2028 | PARVAZ, MUHAMMAD ADEEL | reporter.nih.gov |
| Assessing central muscarinic acetylcholine type-1 receptors in cocaine use disorder with 11C-LSN3172176. | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,664,691 | April 15, 2022 | June 30, 2027 | ANGARITA, GUSTAVO ADOLFO | reporter.nih.gov |
| Synaptic Actions of Amphetamine in the Striatum | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,661,845 | April 1, 2023 | January 31, 2028 | RAYPORT, STEPHEN | reporter.nih.gov |
| Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,661,677 | September 30, 2020 | June 30, 2025 | RAWLS, SCOTT M. | reporter.nih.gov |
| Circuitry and function of ventral striatum subregions | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,660,649 | April 1, 2020 | January 31, 2026 | WESSON, DANIEL W | reporter.nih.gov |
| Role of lateral habenula in methamphetamine TAAR1-mediated synaptic plasticity and aversion | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,656,889 | September 30, 2023 | June 30, 2028 | INGRAM, SUSAN L | reporter.nih.gov |
| Memory Destabilization and Cocaine-Cue Induced Reinstatement in Rat | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,653,750 | July 1, 2021 | April 30, 2027 | TAYLOR, JANE R | reporter.nih.gov |
| L-Type Calcium Channel Mechanisms Mediating Comorbid Substance Use and Mood Disorders | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,645,542 | September 30, 2020 | July 31, 2025 | ADDY, NII A | reporter.nih.gov |
| Structure and Function of Neurotransmitter Transporters | NIH | National Institute of Mental Health | 2021 to 2024 | $1,623,458 | July 1, 2004 | May 31, 2029 | GOUAUX, JAMES E | reporter.nih.gov |
| Development of selective cannabinoid receptor 2 agonists for treatment of addiction | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,621,997 | April 19, 2022 | April 30, 2027 | SHAMLOO, MEHRDAD | reporter.nih.gov |
| Epigenetic regulation of Cdk5 in cognition and emotion | NIH | National Institute of Mental Health | 2023 to 2025 | $1,621,522 | January 1, 2023 | October 31, 2027 | HELLER, ELIZABETH A | reporter.nih.gov |
| The Role of Microbiome Composition in Amphetamine Abuse | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,621,263 | August 15, 2023 | May 31, 2028 | GALLI, AURELIO | reporter.nih.gov |
| Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder | NIH | National Institute on Drug Abuse | 2022 | $1,597,923 | September 30, 2022 | September 29, 2025 | BJORK, JAMES M | reporter.nih.gov |
| Vagus nerve stimulation increases basal dopamine levels in the brain to decrease methamphetamine-mediated responses | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,595,645 | August 1, 2023 | May 31, 2028 | KHOSHBOUEI, HABIBEH | reporter.nih.gov |
| Transgenerational Inheritance of a Cocaine Resistance Phenotype | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,594,735 | April 1, 2012 | January 31, 2027 | PIERCE, ROBERT CHRISTOPHER | reporter.nih.gov |
| Cholinergic interneuron D2 receptor function in impulsive behavior: implications for addiction | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,571,833 | July 1, 2022 | May 31, 2027 | GALLO, EDUARDO FRANCISCO | reporter.nih.gov |
| Supporting Treatment Adherence for Resilience and Thriving (START): A mHealth intervention to improve ART adherence for HIV-positive stimulant-using men | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,555,079 | September 30, 2019 | July 31, 2024 | CARRICO, ADAM WAYNE | reporter.nih.gov |
| Vagus nerve stimulation modulates synaptic plasticity in the rat prefrontal cortex during the extinction of drug-seeking | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,554,112 | April 1, 2022 | January 31, 2027 | KROENER, SVEN | reporter.nih.gov |
| Engaging People Who Use Drugs in Harm Reduction Service Delivery: An Intravention to Reduce Risk of HIV, HCV, Overdose, and Injection-related Infections in Rural Appalachia | NIH | National Institute on Drug Abuse | 2024 | $1,533,697 | September 30, 2024 | August 31, 2026 | YOUNG, APRIL MARIE | reporter.nih.gov |
| Genetic Control of Addiction by Host and Microbiome | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,533,193 | September 30, 2018 | July 31, 2024 | BUBIER, JASON A | reporter.nih.gov |
| Neural circuitry and functional significance of extra-SCN pacemakers | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,529,842 | September 15, 2020 | June 30, 2026 | YAMAZAKI, SHIN | reporter.nih.gov |
| Domain- and protein-selective BET mechanisms in cocaine-seeking behaviors | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,521,368 | August 1, 2023 | May 31, 2028 | SARTOR, GREGORY CHARLES | reporter.nih.gov |
| Effects of intrinsic and drug-induced neuromodulation on functional brain imaging | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,517,943 | August 1, 2020 | May 31, 2025 | DEVOR, ANNA | reporter.nih.gov |
| Role of the NLRP3 Inflammasome in Mediating Microglial Activation and Development of Neuropsychiatric Symptoms Induced by HIV, Antiretrovirals and Cocaine | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,515,246 | August 15, 2021 | June 30, 2024 | GUO, MINGLEI | reporter.nih.gov |
| Pharmacologic augmentation of targeted cognitive training in schizophrenia | NIH | National Institute of Mental Health | 2021 to 2022 | $1,511,158 | August 6, 2020 | July 31, 2024 | SWERDLOW, NEAL R | reporter.nih.gov |
| The neuropharmacology of brain activation during stages of drug abuse | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,503,000 | April 1, 2023 | February 29, 2028 | SANDER, CHRISTIN Y. | reporter.nih.gov |
| Social support, oxytocin and motivation for methamphetamine | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,502,424 | July 15, 2019 | April 30, 2025 | BECKER, JILL B. | reporter.nih.gov |
| Gene Regulation in Memory Circuits as a Consequence of Polysubstance Use | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,500,894 | August 1, 2023 | June 30, 2028 | KAUN, KARLA R. | reporter.nih.gov |
| Phase 0/1b Clinical Trial of Novel Therapeutic Agent MT-110 for the Reduction of Methamphetamine Use - Part 2 | NIH | National Institute on Drug Abuse | 2025 | $1,496,586 | April 1, 2025 | February 28, 2028 | YOUNG, ERICA J | reporter.nih.gov |
| Modular, in-situ probes of brain chemistry | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,496,151 | August 1, 2020 | April 30, 2025 | PLAXCO, KEVIN W | reporter.nih.gov |
| Restoration and Further Assessment of the Actor-Critic Circuit and Connected Areas After Cocaine Self-Administration | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,495,707 | July 1, 2011 | February 29, 2028 | ROESCH, MATTHEW R | reporter.nih.gov |
| Short Sleep Duration as a Predictor of Methamphetamine Intake: Role of Orexin Mechanisms | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,492,883 | July 15, 2024 | April 30, 2029 | BERRO, LAIS F | reporter.nih.gov |
| Deep TMS Neuromodulation of Neural Circuits Associated with Stimulant Use Disorder | NIH | National Institute on Drug Abuse | 2024 | $1,491,755 | September 15, 2024 | August 31, 2026 | PADULA, CLAUDIA B. | reporter.nih.gov |
| A novel opioid receptor antagonist for treating abuse and overdose | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,477,314 | April 1, 2019 | February 28, 2025 | FRANCE, CHARLES P | reporter.nih.gov |
| Assessing the role of corticostriatal circuitry in polysubstance use of fentanyl and methamphetamine using rat self-administration models | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,475,011 | June 15, 2023 | April 30, 2028 | FERGUSON, SUSAN MARIE | reporter.nih.gov |
| Glutamate and Craving for Cocaine | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,472,920 | February 10, 2000 | March 31, 2025 | KALIVAS, PETER W | reporter.nih.gov |
| Examining Mechanisms Underlying Drug-Associated Memory Erasure by Zeta-Inhibitory Peptide | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,470,367 | April 15, 2019 | January 31, 2025 | BRIAND, LISA A | reporter.nih.gov |
| Methamphetamine Activation of Inflammasome and Altered immunity in HIV (MAIA) Study | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,456,335 | September 30, 2024 | July 31, 2029 | PEREIRA RIBEIRO, SUSAN | reporter.nih.gov |
| New Technologies for Accelerating the Discovery and Characterization of Neuroactives that Address Substance Use Disorders | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,453,500 | April 1, 2023 | February 29, 2028 | MCCARROLL, MATTHEW N | reporter.nih.gov |
| Systems genetics of premorbid and cocaine use traits in a rat reduced complexity cross | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,444,164 | May 1, 2022 | December 31, 2023 | KANTAK, KATHLEEN M. | reporter.nih.gov |
| Bath Salts: abuse-related and toxic effects | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,439,490 | April 1, 2015 | March 31, 2026 | COLLINS, GREGORY THOMAS | reporter.nih.gov |
| Identification of Biomarkers of CNS injury and resilience related to HIV-1 and Methamphetamine | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,427,395 | September 15, 2018 | June 30, 2025 | IUDICELLO, JENNIFER E | reporter.nih.gov |
| Experience-Dependent Regulation of Reward Learning and Addiction Vulnerability | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,426,500 | March 1, 2022 | December 31, 2026 | MORIKAWA, HITOSHI | reporter.nih.gov |
| Dissecting the role of ventral pallidal circuitry in cocaine seeking after the withdrawal | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,425,586 | July 15, 2020 | April 30, 2025 | LIM, BYUNGKOOK | reporter.nih.gov |
| Neurotensin receptor 1 as a novel target for opioid use disorder and discovery of new small molecule probes | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,418,702 | September 15, 2024 | May 31, 2029 | SLOSKY, LAUREN M | reporter.nih.gov |
| The impact of poly-substance use on the crosstalk between microglia, astrocytes, and neurons that regulates HIV latency | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,417,276 | May 15, 2024 | February 28, 2029 | KARN, JONATHAN | reporter.nih.gov |
| Targeting autophagy to reduce inflammasome-mediated inflammation and immune dysfunction in HIV and methamphetamine use | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,416,081 | June 1, 2024 | March 31, 2029 | ZHEN, ANJIE | reporter.nih.gov |
| Evaluation of Drug Checking as a Novel Intervention to Address the Opioid Overdose Crisis Attributable to Fentanyl and its Analogues | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,404,636 | September 30, 2021 | January 31, 2026 | TI, LIANPING | reporter.nih.gov |
| Neural Mechanisms of Individual Differences in Cocaine Avoidance | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,404,531 | August 1, 2021 | May 31, 2026 | JHOU, THOMAS C | reporter.nih.gov |
| Impacts of drug abuse-mediated inflammatory perturbations on affinity maturation of anti-CD4 autoantibodies and poor immune reconstitution from ART in HIV | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,402,812 | September 30, 2024 | May 31, 2029 | JIANG, WEI | reporter.nih.gov |
| Modulating ventral striatal activity and connectivity with transcranial focused ultrasound as a putative novel intervention for cocaine use disorder | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,395,182 | June 15, 2024 | May 31, 2027 | PHILLIPS, MARY LOUISE | reporter.nih.gov |
| Selective Targeting of Nicotinic Acetylcholine Receptor Subtypes for Cocaine Use Disorder | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,393,000 | March 1, 2024 | December 31, 2028 | RILEY, ANDREW | reporter.nih.gov |
| Multidisciplinary Characterization of the Gut-Brain Axis in Addiction | NIH | National Center for Complementary & Integrative Health | 2024 | $1,391,376 | September 17, 2024 | August 31, 2027 | CUESTA, SANTIAGO | reporter.nih.gov |
| Estrogen regulation of the prefrontal cortex and drug seeking | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,390,995 | July 1, 2020 | April 30, 2026 | MANTSCH, JOHN R. | reporter.nih.gov |
| Multimodal brain imaging of the neural effects of methylphenidate in patients with ADHD | NIH | National Institute of Mental Health | 2024 to 2025 | $1,382,029 | December 1, 2023 | November 30, 2028 | BIGOS, KRISTIN L | reporter.nih.gov |
| Using Omics to Understand the Effects of Drug Abuse on HIV Latent Reservoir | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,377,622 | August 15, 2018 | May 31, 2025 | JOHNSON, ERIC OTTO | reporter.nih.gov |
| Cell type transcriptional mechanisms of polysubstance choice | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,376,550 | July 1, 2023 | May 31, 2028 | HAMILTON, PETER JAMES | reporter.nih.gov |
| Sleep Disturbances During Cocaine Abstinence, Dopamine Adaptations, and Motivation for Cocaine | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,375,686 | May 1, 2023 | February 29, 2028 | ESPAÑA, RODRIGO A. | reporter.nih.gov |
| Animal Models of Addiction | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,368,000 | December 1, 2018 | November 30, 2024 | FERRARIO, CARRIE | reporter.nih.gov |
| Deep Brain Stimulation (DBS) For Severe Treatment Refractory Methamphetamine Use Disorder | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,366,011 | June 1, 2022 | May 31, 2025 | SAKAI, JOSEPH T | reporter.nih.gov |
| Pathway-specific Intervention in Prelimbic Cortical Circuitry Decreases Cocaine-seeking | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,357,969 | September 30, 2020 | July 31, 2025 | MCGINTY, JACQUELINE F. | reporter.nih.gov |
| Regulating dopamine transport through allosteric modulation - Functional and Behavioral Studies | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,337,160 | September 15, 2024 | May 31, 2029 | MORTENSEN, OLE VALENTE | reporter.nih.gov |
| A novel robotic wastewater analysis system to quantify opioid exposure and treatment in residential communities | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,336,341 | February 1, 2022 | December 31, 2023 | MATUS GARCIA, MARIANA G | reporter.nih.gov |
| 17α-estradiol and sex-differences in HAND with methamphetamine | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,333,494 | September 1, 2023 | July 31, 2028 | CHEN, XUESONG | reporter.nih.gov |
| Dissecting the shared genetic mechanisms driving fentanyl addiction, cocaine addiction, and incentive sensitization using the Collaborative Cross mouse panel | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,331,986 | June 1, 2024 | March 31, 2029 | DICKSON, PRICE EVANS | reporter.nih.gov |
| CELL - AND CIRCUIT - SPECIFIC EXPLORATION OF HIV NEUROGENOMICS IN CONTEXT OF OPIATE AND COCAINE ABUSE | NIH | National Institute on Drug Abuse | 2023 to 2024 | $1,327,322 | June 1, 2019 | March 31, 2026 | AKBARIAN, SCHAHRAM | reporter.nih.gov |
| Systems genetics of premorbid and cocaine use traits in a rat reduced complexity cross | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,325,341 | March 7, 2024 | February 28, 2028 | BRYANT, CAMRON D | reporter.nih.gov |
| Involvement of Cortical Excitatory Projections in Cocaine Addiction | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,324,728 | September 30, 2024 | May 31, 2029 | MA, YAO-YING | reporter.nih.gov |
| Microglial modulation of neurocircuits in HIV/cocaine comorbidity | NIH | National Institute on Drug Abuse | 2023 to 2024 | $1,323,376 | June 1, 2023 | March 31, 2025 | BOOZE, ROSEMARIE M | reporter.nih.gov |
| A cutaneous gene therapy for cocaine abuse and alcohol co-abuse | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,312,200 | September 30, 2019 | July 31, 2025 | XU, MING | reporter.nih.gov |
| Ventral pallidum molecular mediators in cocaine addiction | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,302,852 | February 1, 2019 | November 30, 2024 | LOBO, MARY KAY | reporter.nih.gov |
| Dopamine system as reporter of HIV status and inflammation in Meth abusers | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,302,264 | February 1, 2019 | January 31, 2025 | MARCONDES, MARIA CECILIA GARIBALDI | reporter.nih.gov |
| Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural Function | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,297,577 | July 1, 2018 | April 30, 2024 | LONDON, EDYTHE DANICK | reporter.nih.gov |
| Opioid and Psychostimulant Taking: Testing the Impact of Behavioral Economic Contexts | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,280,955 | September 15, 2022 | July 31, 2027 | KEARNS, DAVID N | reporter.nih.gov |
| Development of the Stimulant Use Disorder Severity Scale | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,280,880 | July 1, 2020 | March 31, 2023 | KILUK, BRIAN D. | reporter.nih.gov |
| Influence of 5-HT1b Activation on the Abuse Related Effects of Cocaine | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,280,534 | August 1, 2021 | July 31, 2025 | STOOPS, WILLIAM WALTON | reporter.nih.gov |
| HIV and cocaine use leads to loss of astrocyte neurotrophic support and impaired lipid homeostasis in the brain | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $1,272,487 | September 20, 2022 | August 31, 2026 | LANGFORD, DIANNE TERESA | reporter.nih.gov |
| The dopamine transporter's lipid interactions: understanding transporter function | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,267,956 | April 1, 2014 | December 31, 2025 | GALLI, AURELIO | reporter.nih.gov |
| Testing Implementation Strategies to Scale-up a Multicomponent Continuum of Service Intervention for Families Involved in Systems with Parental Opioid and Methamphetamine Use | NIH | National Institute on Drug Abuse | 2025 | $1,261,490 | September 15, 2025 | May 31, 2030 | SALDANA, LISA | reporter.nih.gov |
| Dopamine modulation for the treatment of chronic dysfunction due to traumatic brain injury | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,257,620 | May 15, 2019 | April 30, 2025 | VONDER HAAR, COLE | reporter.nih.gov |
| Functional Dynamics of Neurotransmitter:Sodium Symporters (NSSs) | NIH | National Institute of Mental Health | 2024 to 2025 | $1,243,576 | September 12, 2024 | June 30, 2029 | QUICK, MATTHIAS | reporter.nih.gov |
| Antecedents and Consequences of Cocaine Taking: Impact of Oxytocin | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,241,165 | September 1, 2017 | May 31, 2024 | EVANS, SUZETTE M | reporter.nih.gov |
| K channel, NLRP3 inflammasome and Meth exacerbation of HAND | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,234,632 | September 30, 2019 | June 30, 2025 | XIONG, HUANGUI HANK | reporter.nih.gov |
| Identification and Regulation of RNA Modification by HIV infection and Methamphetamine | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,232,056 | April 1, 2018 | January 31, 2025 | RANA, TARIQ M | reporter.nih.gov |
| Human dopamine transporter gene: variation and transcriptional regulation | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,230,000 | September 1, 2007 | July 31, 2025 | LIN, ZHICHENG CARL | reporter.nih.gov |
| Genomic Analysis of Avoidance Learning in Addiction | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,223,491 | April 15, 2018 | June 4, 2023 | JHOU, THOMAS C | reporter.nih.gov |
| A translational determination of the mechanisms of maladaptive choice in cocaine use disorder | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,222,073 | July 1, 2018 | April 30, 2024 | LILE, JOSHUA ANTHONY | reporter.nih.gov |
| Estradiol signaling pathways mediating sex differences in striatal synaptic plasticity | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,218,955 | February 1, 2024 | January 31, 2028 | BLACKWELL, KIM L | reporter.nih.gov |
| Psychostimulant-Induced Plasticity of Nucleus Accumbens Interneurons | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,216,840 | April 1, 2019 | July 31, 2024 | WEST, ANNE ELIZABETH | reporter.nih.gov |
| Diagnostic and prognostic biomarkers for subtypes of addiction-related circuit dysfunction | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,207,946 | August 1, 2019 | May 31, 2024 | LISTON, CONOR M | reporter.nih.gov |
| Low-intensity focused ultrasound for cocaine use disorder: High resolution targeting of the human insula | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,197,126 | August 1, 2022 | January 31, 2025 | AIT-DAOUD, NASSIMA | reporter.nih.gov |
| Trajectories of Prescription Nonmedical Drug Misuse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,194,681 | April 1, 2011 | March 31, 2028 | MCCABE, SEAN ESTEBAN | reporter.nih.gov |
| The role of central GLP-1 receptors in animal models of cocaine addiction | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,188,835 | March 1, 2015 | May 31, 2025 | SCHMIDT, HEATH D | reporter.nih.gov |
| Dissecting the Abuse Liability of Cathinone and Amphetamine Stimulants | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,185,000 | September 30, 2016 | July 31, 2028 | TAFFE, MICHAEL A. | reporter.nih.gov |
| Dissection of Addiction Relevant Signal Integration by Cyfip2 through Precise Genome Engineering | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,178,521 | July 15, 2020 | June 30, 2025 | KUMAR, VIVEK | reporter.nih.gov |
| Methamphetamine, HIV integration and latency in the brain | NIH | National Institute on Drug Abuse | 2023 to 2024 | $1,175,173 | September 30, 2023 | August 31, 2025 | MARCONDES, MARIA CECILIA GARIBALDI | reporter.nih.gov |
| A2: Striosomal models of drug use and cost | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,173,870 | September 15, 2024 | May 31, 2029 | FRIEDMAN, ALEXANDER | reporter.nih.gov |
| Mechanistic studies of alcohol-sleep interactions | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $1,173,750 | September 17, 2019 | August 31, 2025 | TORREGROSSA, MARY M | reporter.nih.gov |
| Incubation of oxycodone craving and nucleus accumbens plasticity | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,166,080 | September 30, 2024 | May 31, 2029 | WOLF, MARINA ELIZABETH | reporter.nih.gov |
| Neuronal exosomes in cocaine abuse and treatment response in socially housed monkeys | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,162,500 | July 1, 2019 | April 30, 2025 | DEEP, GAGAN | reporter.nih.gov |
| Molecular determinants of ensemble recruitment by drugs of abuse | NIH | National Institute on Drug Abuse | 2025 | $1,159,396 | July 1, 2025 | March 31, 2030 | CALIPARI, ERIN | reporter.nih.gov |
| Novel 5-HT2A/mGluR5 Antagonist for Opioid Use Disorder | NIH | National Institute on Drug Abuse | 2025 | $1,153,945 | September 15, 2025 | August 31, 2027 | MOELLER, FREDERICK GERARD | reporter.nih.gov |
| The role of norepinephrine transporter phosphorylation in amphetamine reward | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,152,433 | September 15, 2024 | July 31, 2029 | JAYANTHI, LANKUPALLE D | reporter.nih.gov |
| Inflammasome Activation and Gut-Brain Axis Dysregulation in HIV and Methamphetamine-Associated Depression | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,146,614 | March 15, 2024 | January 31, 2029 | TOBOREK, MICHAL | reporter.nih.gov |
| Targeted CRISPR/Cas Editing to Eliminate SIV CNS Reservoir in Methamphetamine-Exposed Rhesus Macaques on ART | NIH | National Institute on Drug Abuse | 2025 | $1,144,344 | August 15, 2025 | May 31, 2030 | LING, BINHUA "JULIE" | reporter.nih.gov |
| Defining molecular mechanisms by which stimulant evoked dopamine drives inflammation and neuronal dysfunction in neuroHIV | NIH | National Institute on Drug Abuse | 2023 to 2024 | $1,142,172 | July 1, 2023 | June 30, 2025 | GASKILL, PETER JESSE | reporter.nih.gov |
| Identifying patterns of human polysubstance use to guidedevelopment of rodent models | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,138,416 | September 30, 2018 | June 30, 2024 | KNACKSTEDT, LORI A | reporter.nih.gov |
| Extracellular vesicles, meth relapse and sex differences | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,120,035 | September 30, 2018 | June 30, 2024 | PENDYALA, GURUDUTT | reporter.nih.gov |
| Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $1,108,211 | August 16, 2018 | July 31, 2025 | MARKOWITZ, JOHN S | reporter.nih.gov |
| Establishing a link between habits and punishment resistance | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,106,838 | February 15, 2019 | December 31, 2025 | SMITH, RACHEL J | reporter.nih.gov |
| Role of astrocytes in dopamine signaling and psychostimulant effects | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,097,250 | August 1, 2019 | May 31, 2025 | ARAQUE, ALFONSO | reporter.nih.gov |
| Zona Incerta Contributions to Reward and Cocaine Addiction | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,097,250 | September 15, 2019 | June 30, 2025 | LIU, QING-SONG | reporter.nih.gov |
| Functional consequences of cocaine self-administration on astrocytes | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,086,725 | May 1, 2023 | February 29, 2028 | REISSNER, KATHRYN JOANNA | reporter.nih.gov |
| In-utero exposure to psychotropic medications and the risk of neurodevelopmental disorders | NIH | National Institute of Mental Health | 2021 to 2022 | $1,078,742 | June 15, 2018 | December 31, 2023 | HUYBRECHTS, KRISTA F | reporter.nih.gov |
| Multimodal profiling of microglia during HIV infection and substance use disorder | NIH | National Institute on Drug Abuse | 2023 to 2024 | $1,076,164 | September 30, 2023 | August 31, 2025 | JORDAN-SCIUTTO, KELLY L | reporter.nih.gov |
| Developing a sleep EEG-based biomarker for drug relapse propensity | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,075,270 | April 15, 2024 | January 31, 2029 | HUANG, YANHUA H | reporter.nih.gov |
| ROLE OF OREXIN IN COCAINE DEMAND AND ADDICTION | NIH | National Institute on Drug Abuse | 2023 to 2024 | $1,067,550 | August 1, 1992 | November 30, 2025 | ASTON-JONES, GARY S. | reporter.nih.gov |
| Long-acting aldicarb hydrolase as a medical countermeasure for aldicarb poisoning | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $1,065,924 | September 1, 2023 | August 31, 2025 | ZHENG, FANG | reporter.nih.gov |
| Investigating the mechanistic contribution of Cav1.2 channels in extinction of cocaine-associated memories | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,063,494 | April 1, 2022 | October 31, 2023 | RAJADHYAKSHA, ANJALI M | reporter.nih.gov |
| Mechanistic studies of cAMP effectors in cocaine addiction | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,062,600 | April 15, 2014 | May 31, 2025 | LIU, QING-SONG | reporter.nih.gov |
| COMT inhibition as a potential therapeutic target among individuals with comorbid Alcohol Use Disorder and Attention-Deficit/Hyperactivity Disorder | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $1,057,280 | April 20, 2019 | March 31, 2025 | SCHACHT, JOSEPH P. | reporter.nih.gov |
| Sleep regulates drug relapse and addiction | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,056,375 | April 1, 2019 | January 31, 2025 | HUANG, YANHUA H | reporter.nih.gov |
| Dopamine Transporter Cell Surface Dynamics | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,051,580 | May 1, 2013 | March 31, 2024 | MELIKIAN, HALEY E | reporter.nih.gov |
| Encoding dopamine signals in the mesolimbic system | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,049,625 | August 1, 2013 | February 28, 2025 | FORD, CHRISTOPHER PETER | reporter.nih.gov |
| ROLE OF OREXIN IN COCAINE DEMAND AND ADDICTION | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,048,129 | August 1, 1992 | November 30, 2022 | ASTON-JONES, GARY S. | reporter.nih.gov |
| Pharmacology of Stimulant Choice | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,047,939 | April 15, 2023 | February 29, 2028 | BANKS, MATTHEW L | reporter.nih.gov |
| Extensive drug histories result in compulsive appetite: functional identification of punishment-reactive neural network re-organization in the rostromedial tegmental nucleus | NIH | National Institute on Drug Abuse | 2022 to 2023 | $1,042,506 | September 1, 2022 | April 26, 2024 | SUTO, NOBUYOSHI | reporter.nih.gov |
| Reprogramming KZFP function to understand drug-specific transcription and behavior | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,040,268 | May 1, 2024 | February 28, 2029 | HAMILTON, PETER JAMES | reporter.nih.gov |
| Amphetamine in adolescence disrupts frontal cortex development | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,035,897 | April 1, 2015 | July 31, 2025 | FLORES, CECILIA | reporter.nih.gov |
| Investigating the mechanistic contribution of Cav1.2 channels in extinction of cocaine-associated memories | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,031,426 | July 1, 2020 | January 31, 2027 | RAJADHYAKSHA, ANJALI M | reporter.nih.gov |
| Neural Mechanisms of Individual Differences in Cocaine Avoidance | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,031,082 | August 1, 2021 | May 31, 2023 | JHOU, THOMAS C | reporter.nih.gov |
| Characterization of cortical neuronal subtypes in cocaine self-administration | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,029,911 | August 15, 2019 | May 31, 2023 | FERGUSON, SUSAN MARIE | reporter.nih.gov |
| An integrated incentive-based treatment to optimize HIV treatment engagement among persons who use methamphetamine | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,028,700 | May 1, 2021 | April 30, 2027 | MONTOYA, JESSICA LYNETTE | reporter.nih.gov |
| Epigenetic regulation of astrocyte-specific NLRP6 inflammasome and PANoptosis in HIV Tat and methamphetamine-mediated neuroinflammation | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,023,771 | July 1, 2024 | April 30, 2029 | PERIYASAMY, PALSAMY | reporter.nih.gov |
| Serotonin receptors that potentiate addiction-related behavioral and molecular effects induced by methylphenidate plus SSRI exposure | NIH | National Institute on Drug Abuse | 2021 to 2023 | $1,013,596 | April 1, 2019 | January 31, 2024 | STEINER, HEINZ | reporter.nih.gov |
| Effects of methamphetamine use on risk behavior, systemic and mucosal inflammation, and sexually transmitted infection (STI)/HIV risk among men who have sex with men | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,011,960 | July 15, 2021 | June 30, 2027 | BLAIR, CHERIE SAVINE | reporter.nih.gov |
| Transgenerational Inheritance of a Cocaine Resistance Phenotype | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,009,002 | April 1, 2012 | January 31, 2023 | PIERCE, ROBERT CHRISTOPHER | reporter.nih.gov |
| Investigations into 5-HT2A signaling mechanisms of psychedelic drugs for the treatment of stimulant use disorder | NIH | National Institute on Drug Abuse | 2024 to 2025 | $989,771 | May 15, 2024 | March 31, 2029 | MCCORVY, JOHN D | reporter.nih.gov |
| Brain endothelial EVs role in the neuropathology of drugs of abuse and HIV | NIH | National Institute on Drug Abuse | 2021 to 2022 | $987,280 | September 30, 2018 | June 30, 2023 | RAMIREZ, SERVIO HEYBERT | reporter.nih.gov |
| Impacts of Recreational Marijuana Legalization and Retail Outlets in Washington: Unique Perspectives from Survey and County Mortality Data | NIH | National Institute on Drug Abuse | 2021 to 2022 | $986,098 | July 1, 2019 | May 31, 2024 | KERR, WILLIAM C. | reporter.nih.gov |
| The Genetic and Epigenetic Interplay of Cocaine Addiction: A Cell-Type, Circuitry, and Functional Dissection | NIH | National Institute on Drug Abuse | 2024 to 2025 | $984,000 | August 1, 2024 | June 30, 2029 | ZHANG, ZHUZHU | reporter.nih.gov |
| In situ spatial characterization of CNS HIV-host cellular interactions from victims of sudden death | NIH | National Institute on Drug Abuse | 2024 to 2025 | $983,744 | September 30, 2024 | July 31, 2027 | HENRICH, TIMOTHY JENSEN | reporter.nih.gov |
| Cyclic Peptides to Treat Cocaine Use Disorder | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $981,998 | May 15, 2023 | April 30, 2026 | ALDRICH, JANE V | reporter.nih.gov |
| Glutide for Ending Methamphetamine | NIH | National Institute on Drug Abuse | 2025 | $977,129 | September 1, 2025 | August 31, 2027 | COFFIN, PHILLIP O | reporter.nih.gov |
| Differential Roles of Prefrontal Cortical Interneurons in Drug Seeking after Withdrawal | NIH | National Institute on Drug Abuse | 2024 to 2025 | $972,206 | July 1, 2024 | April 30, 2029 | LIM, BYUNGKOOK | reporter.nih.gov |
| Decoding ensemble dynamics from cortico-amygdalar circuits during social choice | NIH | National Institute of Mental Health | 2023 to 2025 | $965,142 | August 1, 2023 | July 31, 2028 | ALLSOP, AZA STEPHEN | reporter.nih.gov |
| Hypocretinergic control of cocaine abuse | NIH | National Institute on Drug Abuse | 2021 to 2022 | $964,962 | September 30, 2018 | June 30, 2023 | HORVATH, TAMAS L | reporter.nih.gov |
| Drug Abuse and Related Health Disparities: An Intergenerational Longitudinal Study of Offspring of Delinquent Youth (Northwestern Offspring Project) | NIH | National Institute on Drug Abuse | 2021 to 2022 | $961,334 | September 1, 2018 | May 31, 2025 | TEPLIN, LINDA A | reporter.nih.gov |
| Regulation of monoamine neurons by delta glutamate receptors | NIH | National Institute on Drug Abuse | 2024 to 2025 | $961,242 | April 1, 2024 | January 31, 2029 | GANTZ, STEPHANIE C. | reporter.nih.gov |
| Optimization of novel thioesters as a therapeutic strategy for combating opioid overdoses and abuse | NIH | National Institute on Drug Abuse | 2021 to 2022 | $956,514 | September 1, 2020 | July 31, 2023 | LEWIS, STEPHEN JOHN | reporter.nih.gov |
| Epitranscriptomic Regulation of Synaptic Responses to Drugs of Abuse | NIH | National Institute on Drug Abuse | 2021 to 2022 | $954,795 | July 15, 2018 | June 30, 2024 | MEYER, KATHRYN D | reporter.nih.gov |
| Getting Off: A Theory-based mHealth Intervention for Methamphetamine-using MSM | NIH | National Institute on Drug Abuse | 2021 to 2022 | $953,199 | July 15, 2018 | April 30, 2024 | REBACK, CATHY J | reporter.nih.gov |
| Trajectories of socially regulated gene expression, methamphetamine use, and viral load among HIV-positive men who have sex with men (MSM) receiving contingency management | NIH | National Institute on Drug Abuse | 2021 to 2025 | $947,005 | April 1, 2021 | March 31, 2026 | LI, MICHAEL JONATHAN | reporter.nih.gov |
| Cyclic Peptides to Treat Cocaine Use Disorder | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $945,491 | May 15, 2023 | April 30, 2024 | ALDRICH, JANE V | reporter.nih.gov |
| Deep Analysis of Transcriptome to Understand the Genetics of Substance Use Disorders in Rats | NIH | National Institute on Drug Abuse | 2025 | $944,888 | July 1, 2025 | March 31, 2030 | MOHAMMADI, PEJMAN | reporter.nih.gov |
| The ION+EMI Study: Intermittent Oral Naltrexone enhanced with an Ecological Momentary Intervention for Methamphetamine-using MSM | NIH | National Institute on Drug Abuse | 2021 to 2023 | $944,445 | September 1, 2021 | July 31, 2025 | SANTOS, GLENN-MILO | reporter.nih.gov |
| Mentoring patient-oriented research on the health consequences of polydrug use | NIH | National Institute on Drug Abuse | 2021 to 2025 | $941,480 | July 1, 2015 | June 30, 2027 | RILEY, ELISE D. | reporter.nih.gov |
| Extensive drug histories result in compulsive appetite: functional identification of punishment-reactive neural network re-organization in the rostromedial tegmental nucleus | NIH | National Institute on Drug Abuse | 2024 to 2025 | $939,600 | July 15, 2024 | June 30, 2027 | SUTO, NOBUYOSHI | reporter.nih.gov |
| Cocaine Abstinence or Reduced Use May Retard Alterations in Brain Structure and Function, and Associated Cognitive Changes among African American Cocaine Users with HIV | NIH | National Institute on Drug Abuse | 2024 | $939,459 | May 1, 2024 | February 28, 2029 | LAI, SHENGHAN | reporter.nih.gov |
| Molecular Pathways of Innate Immunity and Substance Abuse in NeuroHIV | NIH | National Institute on Drug Abuse | 2023 to 2024 | $927,683 | September 30, 2023 | July 31, 2025 | INACIO MAMEDE, JOAO FILIPE | reporter.nih.gov |
| Transcutaneous Phrenic Nerve Stimulation for Treating Opioid Overdose | NIH | National Institute on Drug Abuse | 2023 | $927,319 | September 1, 2023 | August 31, 2025 | LEVIN, HOWARD | reporter.nih.gov |
| Characterization of cocaine induced signaling pathways that enhances HIV transcription | NIH | National Institute on Drug Abuse | 2021 to 2023 | $916,120 | September 1, 2017 | April 30, 2026 | TYAGI, MUDIT | reporter.nih.gov |
| Toward Repurposing a Commonly-Used Medication for the Treatment of Pediatric Severe Obesity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $914,862 | August 15, 2023 | June 30, 2027 | FOX, CLAUDIA K | reporter.nih.gov |
| Examination of epigenetic spatial architecture in the CNS as a method to understand cocaine relapse in ecoHIV infected mice | NIH | National Institute on Drug Abuse | 2024 to 2025 | $908,940 | September 30, 2024 | November 30, 2026 | KLASE, ZACHARY ALAN | reporter.nih.gov |
| SCH: Multidimensional Data Science Approach: Measuring and Characterizing Craving and Affective Profiles in Substance Use Disorders | NIH | National Institute on Drug Abuse | 2023 to 2025 | $900,000 | August 1, 2023 | June 30, 2027 | SANO, AKANE | reporter.nih.gov |
| Cannabinoid inhibition of CNS inflammasome activation via modulation of the gut-brain axis | NIH | National Institute on Drug Abuse | 2025 | $898,025 | April 15, 2025 | February 28, 2030 | BYRAREDDY, SIDDAPPA N | reporter.nih.gov |
| Chemokine CXCL12/CXCR4 system and synthetic cathinones | NIH | National Institute on Drug Abuse | 2021 to 2022 | $894,344 | July 1, 2018 | April 30, 2024 | RAWLS, SCOTT M. | reporter.nih.gov |
| High-throughput identification and characterization of conserved regulators of drug-induced plasticity using single-neuron resolution atlases of the complete Caenorhabditis elegans nervous system | NIH | National Institute on Drug Abuse | 2024 to 2025 | $891,000 | September 30, 2024 | July 31, 2029 | SUN, HAOSHENG | reporter.nih.gov |
| Development and Testing of a Mobile Application to Enhance HIV Prevention Cascade in Malaysian MSM | NIH | Fogarty International Center | 2022 to 2024 | $884,507 | January 1, 2020 | June 30, 2026 | SHRESTHA, ROMAN | reporter.nih.gov |
| Elucidating Ih Biophysical Epigenetic Modifications in VTA Dopaminergic Neurons after Contingent and Non-Contingent Cocaine Administration | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $884,337 | July 15, 2022 | June 30, 2027 | JIMENEZ-RIVERA, CARLOS A | reporter.nih.gov |
| Investigating Parkin-mediated Neuronal Energy Maintenance in Methamphetamine Use Disorder | NIH | National Institute on Drug Abuse | 2023 to 2025 | $881,915 | September 30, 2023 | June 30, 2028 | MOSZCZYNSKA, ANNA | reporter.nih.gov |
| Retinoic acid signaling: a novel factor for addiction-related behavior | NIH | National Institute on Drug Abuse | 2021 to 2022 | $864,126 | September 15, 2018 | June 30, 2024 | GREEN, THOMAS ARTHUR | reporter.nih.gov |
| Patient Navigator plus Remote mHealth Adherence Support with Incentives: Understanding Criminal Justice Effects | NIH | National Institute on Drug Abuse | 2022 to 2023 | $841,820 | September 30, 2023 | September 29, 2024 | TSUI, JUDITH | reporter.nih.gov |
| Assessing central muscarinic acetylcholine type-1 receptors in cocaine use disorder with 11C-LSN3172176. | NIH | National Institute on Drug Abuse | 2022 to 2023 | $837,270 | April 15, 2022 | June 30, 2024 | WORHUNSKY, PATRICK D | reporter.nih.gov |
| Cognitively-enhanced tDCS of the dorsolateral prefrontal cortex to reduce craving in cocaine addiction | NIH | National Institute on Drug Abuse | 2025 | $833,825 | May 1, 2025 | February 28, 2030 | GOLDSTEIN, RITA Z | reporter.nih.gov |
| Role of prelimbic cortical endocannabinoid signaling in enhanced cocaine-seeking behavior following combined repeated stress and cocaine use in rats | NIH | National Institute on Drug Abuse | 2024 to 2025 | $832,475 | March 1, 2024 | January 31, 2029 | MCREYNOLDS, JAYME ROSE | reporter.nih.gov |
| Expanding the Scope and Usability of Fast Voltammetric Measurements | NIH | National Institute on Drug Abuse | 2024 to 2025 | $832,134 | September 15, 2024 | July 31, 2029 | SOMBERS, LESLIE A | reporter.nih.gov |
| Cue Reactivity Modulation in MSM with Methamphetamine Use Disorder | NIH | National Institute on Drug Abuse | 2023 to 2024 | $827,884 | September 30, 2023 | March 21, 2025 | PARVAZ, MUHAMMAD ADEEL | reporter.nih.gov |
| The Sex-specific Roles and Neural Processing Correlates of Future Outcome Estimation in the Drug Addiction Process | NIH | National Institute on Drug Abuse | 2021 to 2022 | $822,627 | July 1, 2018 | April 30, 2024 | JAMES, GEORGE ANDREW | reporter.nih.gov |
| B1 noradrenergic blockade in early withdrawal to reduce cocaine induced behavioral flexibility deficit | NIH | National Institute on Drug Abuse | 2021 to 2022 | $818,813 | March 1, 2020 | February 29, 2024 | WEST, ELIZABETH A | reporter.nih.gov |
| Short-term Outcome of Stimulant Use Disorder Treatment Trials | NIH | National Institute on Drug Abuse | 2022 to 2023 | $818,750 | August 1, 2022 | January 31, 2024 | MOJTABAI, RAMIN | reporter.nih.gov |
| Basolateral amygdala dopamine in addiction-related learning strategies | NIH | National Institute on Drug Abuse | 2024 to 2025 | $818,513 | September 15, 2024 | May 31, 2029 | SAUNDERS, BENJAMIN THOMAS | reporter.nih.gov |
| Development and Validation of a Stimulant Use Disorder Severity Scale | NIH | National Institute on Drug Abuse | 2025 | $818,486 | July 15, 2025 | June 30, 2027 | KILUK, BRIAN D. | reporter.nih.gov |
| Cognitive Reappraisal for Mitigating Incubation of Cocaine Cue-Reactivity | NIH | National Institute on Drug Abuse | 2023 | $815,875 | September 30, 2023 | August 31, 2028 | PARVAZ, MUHAMMAD ADEEL | reporter.nih.gov |
| Development of therapeutic candidates for stimulant use disorder using AI-driven platform for focused drug discovery and accelerated development | NIH | National Institute on Drug Abuse | 2025 | $811,876 | July 15, 2025 | July 31, 2028 | VARSHNEY, JYOTIKA | reporter.nih.gov |
| Strength in HEALing: Indigenous Community-Led Strategies to Treat Stimulant Use | NIH | National Institute on Drug Abuse | 2024 | $809,042 | September 30, 2024 | August 31, 2026 | HIRCHAK, KATHERINE | reporter.nih.gov |
| Computational Methods for Identification of Genetic Factors Affecting the Response to Drug Abuse | NIH | National Institute on Drug Abuse | 2021 to 2022 | $807,872 | September 1, 2017 | June 30, 2023 | PELTZ, GARY A | reporter.nih.gov |
| Methamphetamine and Cysteinyl Leukotrienes in HIV Persistence | NIH | National Institute on Drug Abuse | 2025 | $804,728 | June 1, 2025 | April 30, 2030 | KAUL, MARCUS | reporter.nih.gov |
| Together Against Overdose: community developed technology to encourage drug checking, distribution of harm reduction supplies, and linkage to services | NIH | National Institute on Drug Abuse | 2024 | $803,573 | September 30, 2024 | August 31, 2026 | ARONSON, IAN DAVID | reporter.nih.gov |
| Genetic substrates of cue-reactivity and cocaine motivation | NIH | National Institute on Drug Abuse | 2025 | $802,735 | August 1, 2025 | April 30, 2030 | MEYER, PAUL J | reporter.nih.gov |
| Developing nonmuscle myosin II inhibitors for the treatment of glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $802,521 | January 1, 2021 | December 31, 2024 | MILLER, COURTNEY A | reporter.nih.gov |
| Methamphetamine, HIV integration and latency in the brain | NIH | National Institute on Drug Abuse | 2025 | $798,422 | September 30, 2023 | August 31, 2028 | MARCONDES, MARIA CECILIA GARIBALDI | reporter.nih.gov |
| Discovery of GPR52 ligand probes for cocaine use disorder | NIH | National Institute on Drug Abuse | 2025 | $795,090 | September 1, 2025 | May 31, 2030 | ALLEN, JOHN A | reporter.nih.gov |
| Role of miRNAs in Methamphetamine/HIV-mediated Immune Activation | NIH | National Institute on Drug Abuse | 2021 to 2022 | $792,500 | April 1, 2018 | February 29, 2024 | HO, WENZHE | reporter.nih.gov |
| Reversing Cocaine-induced Impairments in the NAc with Controllable Stressors | NIH | National Institute on Drug Abuse | 2021 to 2022 | $782,589 | September 30, 2018 | August 31, 2024 | SADDORIS, MICHAEL | reporter.nih.gov |
| Interplay between limbic norepinephrine and dopamine circuits in reward and aversion | NIH | National Institute on Drug Abuse | 2025 | $781,032 | August 1, 2025 | April 30, 2030 | PARK, JINWOO | reporter.nih.gov |
| Novel anti-cocaine D1 partial agonists | NIH | National Institute on Drug Abuse | 2021 to 2022 | $780,000 | May 1, 2019 | April 30, 2024 | HARDING, WAYNE WESLEY | reporter.nih.gov |
| Analyzing Sequential, Multiple Assignment, Randomized Trials in the Presence of Partial Compliance | NIH | National Institute on Drug Abuse | 2021 to 2022 | $769,466 | September 30, 2019 | August 31, 2024 | ERTEFAIE, ASHKAN | reporter.nih.gov |
| Addiction liability, poor attentional control, and cholinergic deficiency | NIH | National Institute on Drug Abuse | 2021 to 2022 | $768,539 | September 15, 2018 | June 30, 2023 | SARTER, MARTIN F | reporter.nih.gov |
| THE ROLE OF RYANODINE RECEPTORS IN DRUG SEEKING | NIH | National Institute on Drug Abuse | 2021 to 2022 | $767,162 | July 15, 2018 | May 31, 2024 | RIEGEL, ARTHUR C | reporter.nih.gov |
| Supporting Treatment Adherence for Resilience and Thriving (START): A mHealth intervention to improve ART adherence for HIV-positive stimulant-using men | NIH | National Institute on Drug Abuse | 2023 | $762,759 | August 1, 2023 | July 31, 2025 | CARRICO, ADAM WAYNE | reporter.nih.gov |
| Cocaine Addition and the Need-State Hypothesis | NIH | National Institute on Drug Abuse | 2025 | $762,063 | May 1, 2025 | February 28, 2030 | GRIGSON, PATRICIA SUE | reporter.nih.gov |
| Our Healing Journey: A Cultural and Traditional Response to the Opioid Epidemic | NIH | National Institute on Drug Abuse | 2024 to 2025 | $759,957 | August 15, 2024 | July 31, 2026 | WEBB, KELLIE | reporter.nih.gov |
| NOP receptors as targets for novel pharmacotherapies for cocaine use disorder in nonhuman primate models | NIH | National Institute on Drug Abuse | 2025 | $758,218 | September 1, 2025 | May 31, 2030 | CZOTY, PAUL W. | reporter.nih.gov |
| Concussion and Attention-Deficit/Hyperactivity Disorder: Investigating the relationship between cognitive outcome, prescription stimulants, and functional MRI biomarkers in the ABCD study. | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $758,064 | April 1, 2022 | March 31, 2027 | KAY, BENJAMIN PAUL | reporter.nih.gov |
| Addressing negative social experiences through coping and resilience to reduce methamphetamine use and improve PrEP cascade progression among Latino MSM | NIH | National Institute on Drug Abuse | 2022 to 2025 | $754,144 | September 1, 2022 | August 31, 2027 | ALGARIN, ANGEL B | reporter.nih.gov |
| Identification of Neural Markers of Aggression and Irritability and Their Capacity to Predict Treatment Response to CNS Stimulant Medication in Youth with ADHD | NIH | National Institute of Mental Health | 2025 | $752,854 | June 1, 2025 | May 31, 2030 | WAXMONSKY, JAMES GAIER | reporter.nih.gov |
| Role of the NLRP3 Inflammasome in Mediating Microglial Activation and Development of Neuropsychiatric Symptoms Induced by HIV, Antiretrovirals and Cocaine | NIH | National Institute on Drug Abuse | 2024 to 2025 | $751,970 | August 15, 2021 | June 30, 2027 | GUO, MINGLEI | reporter.nih.gov |
| The Role of HIV Proteins in Psychostimulant Abuse | NIH | National Institute on Drug Abuse | 2025 | $751,112 | May 1, 2025 | March 31, 2030 | GALLI, AURELIO | reporter.nih.gov |
| Cucurbituril Type Receptors as Sequestration Agents for Drugs of Abuse | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $747,910 | April 15, 2019 | January 31, 2024 | ISAACS, LYLE D | reporter.nih.gov |
| Role of Class IIa HDAC Target Genes in Opioid and Cocaine Addiction | NIH | National Institute on Drug Abuse | 2021 to 2022 | $747,500 | July 1, 2013 | May 31, 2024 | COWAN, CHRISTOPHER W | reporter.nih.gov |
| The protective effect of volitional social interaction on drug addiction | NIH | National Institute on Drug Abuse | 2021 to 2023 | $747,000 | May 1, 2021 | April 30, 2025 | VENNIRO, MARCO | reporter.nih.gov |
| Leveraging Functional Selectivity in the Neurotensin Receptor 1-Mediated Treatment of Addiction | NIH | National Institute on Drug Abuse | 2022 to 2024 | $747,000 | June 15, 2019 | December 31, 2024 | SLOSKY, LAUREN M | reporter.nih.gov |
| Sex Differences in Addiction | NIH | National Institute on Drug Abuse | 2022 to 2024 | $747,000 | March 1, 2019 | February 28, 2026 | KOHTZ, AMY | reporter.nih.gov |
| Role of orexin receptors in the abuse- and sleep-related effects of methamphetamine | NIH | National Institute on Drug Abuse | 2022 to 2024 | $747,000 | August 1, 2020 | July 31, 2026 | BERRO, LAIS F | reporter.nih.gov |
| Effects of exercise on dopaminergic mechanisms of cocaine relapse | NIH | National Institute on Drug Abuse | 2022 to 2024 | $746,997 | August 1, 2019 | February 28, 2026 | ZLEBNIK, NATALIE | reporter.nih.gov |
| Circuit Mechanisms for Conditioned Stress Regulation of Addiction | NIH | National Institute on Drug Abuse | 2022 to 2024 | $746,997 | July 15, 2019 | June 30, 2026 | GARCIA KELLER, CONSTANZA | reporter.nih.gov |
| Reducing co-occurring substance use and HIV risk among stimulant-using men at high risk for HIV in the United States of America. | NIH | National Institute on Drug Abuse | 2023 to 2025 | $746,997 | June 1, 2021 | May 31, 2027 | COLON-BURGOS, JOSE FELIX | reporter.nih.gov |
| Orexin (hypocretin) signaling in ventral tegmental area as a common mediator of sleep disturbances and drug demand in cocaine abstinence | NIH | National Institute on Drug Abuse | 2024 to 2025 | $745,734 | July 15, 2024 | May 31, 2029 | ASTON-JONES, GARY S. | reporter.nih.gov |
| Neural circuitry of distress tolerance | NIH | National Institute on Drug Abuse | 2021 to 2023 | $745,315 | March 1, 2019 | February 28, 2025 | MOSCHAK, TRAVIS M | reporter.nih.gov |
| Role of Nucleus Accumbens D2-expressing Neurons in Punished Cocaine Seeking | NIH | National Institute on Drug Abuse | 2021 to 2023 | $744,648 | April 1, 2019 | April 30, 2025 | VENTO, PETER J. | reporter.nih.gov |
| Multimodal profiling of microglia during HIV infection and substance use disorder | NIH | National Institute on Drug Abuse | 2025 | $744,484 | September 30, 2023 | August 31, 2028 | JORDAN-SCIUTTO, KELLY L | reporter.nih.gov |
| Hypocretin/Orexin Regulation of Dopamine Signaling and Cocaine Reinforcement | NIH | National Institute on Drug Abuse | 2021 to 2022 | $742,144 | January 1, 2013 | May 31, 2025 | ESPAÑA, RODRIGO A. | reporter.nih.gov |
| Improving retention in care for persons with HIV who use substances by increasing acceptance and reducing stigma | NIH | National Institute on Drug Abuse | 2021 to 2023 | $736,694 | June 1, 2021 | May 31, 2025 | MOITRA, ETHAN | reporter.nih.gov |
| Unpredictable availability as a determinant of drug-related outcomes | NIH | National Institute on Drug Abuse | 2021 to 2022 | $736,250 | April 1, 2018 | March 31, 2025 | HUSKINSON, SALLY | reporter.nih.gov |
| Molecular Pathways of Innate Immunity and Substance Abuse in NeuroHIV | NIH | National Institute on Drug Abuse | 2025 | $733,223 | September 30, 2023 | July 31, 2028 | I. MAMEDE, JOAO | reporter.nih.gov |
| Advancing Non-Abstinence Outcomes in the Treatment of Methamphetamine Use Disorder | NIH | National Institute on Drug Abuse | 2025 | $731,997 | September 30, 2025 | May 31, 2030 | STOOPS, WILLIAM WALTON | reporter.nih.gov |
| Prescription Stimulant Supply Shocks: Assessing the Impacts on Health Outcomes and Disparities | NIH | National Institute of Mental Health | 2025 | $729,367 | December 18, 2024 | November 30, 2028 | SMART, ROSANNA | reporter.nih.gov |
| Augmenting cognitive-behavioral therapy with rTMS of the medial prefrontal and anterior cingulate cortices for the treatment of cocaine use disorder | NIH | National Institute on Drug Abuse | 2023 | $728,927 | May 15, 2023 | April 30, 2027 | MARTINEZ, DIANA M | reporter.nih.gov |
| Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1Tat and cocaine | NIH | National Institute on Drug Abuse | 2025 | $728,575 | May 15, 2025 | April 30, 2029 | ZHU, JUN | reporter.nih.gov |
| Training in MHealth Prevention with MSM | NIH | National Institute on Drug Abuse | 2021 to 2024 | $725,604 | July 15, 2020 | June 30, 2026 | SHRESTHA, ROMAN | reporter.nih.gov |
| Intervention to Reduce Internalized Stigma (IRIS) among People Living with HIV who use Substances | NIH | National Institute on Drug Abuse | 2022 to 2024 | $724,401 | September 1, 2022 | July 31, 2026 | FLETCHER, JESSE BRADFORD | reporter.nih.gov |
| Mechanisms underlying dysregulated neuroimmune signaling and neuronal dysfunction in HIV (+) individuals with cART and cocaine | NIH | National Institute on Drug Abuse | 2021 to 2022 | $724,376 | September 30, 2018 | July 31, 2025 | BUCH, SHILPA J. | reporter.nih.gov |
| Adaption of the STAIR-NT Trauma Intervention for Polysubstance Populations | NIH | National Institute on Drug Abuse | 2022 | $723,155 | September 30, 2022 | September 29, 2025 | BUNTING, AMANDA M | reporter.nih.gov |
| A longitudinal analysis of methamphetamine use, social relationships, and cognitive function among people living with HIV | NIH | National Institute on Drug Abuse | 2021 to 2024 | $720,272 | September 30, 2021 | July 31, 2026 | BENDER, ALEXIS ANNE | reporter.nih.gov |
| Oxytocin and drug extinction in prairie voles | NIH | National Institute on Drug Abuse | 2025 | $718,146 | August 15, 2025 | April 30, 2030 | KABBAJ, MOHAMED | reporter.nih.gov |
| Transporting treatment effects from clinical trials to real-world populations with co-occurring opioid and stimulant use disorders | NIH | National Institute on Drug Abuse | 2022 to 2025 | $714,130 | July 1, 2022 | June 30, 2027 | COOK, RYAN | reporter.nih.gov |
| Virtual Reality-Augmented Future Orientation in Stimulant Use Disorder Recovery | NIH | National Institute on Drug Abuse | 2022 to 2024 | $713,250 | May 1, 2022 | April 30, 2026 | OBERLIN, BRANDON | reporter.nih.gov |
| The Mechanistic Role of Visual Areas at the Interaction of Social Behavior and Drug Effects in Nonhuman Primates | NIH | National Institute on Drug Abuse | 2025 | $712,500 | September 1, 2025 | May 31, 2030 | PONCE, CARLOS RAMON | reporter.nih.gov |
| Cortical Plasticity in Methamphetamine Addiction | NIH | National Institute on Drug Abuse | 2021 to 2022 | $710,126 | September 15, 2012 | June 30, 2024 | SCOFIELD, MICHAEL DAVID | reporter.nih.gov |
| Repurposing Semaglutide for the Treatment of Cocaine Use Disorder: a Pilot Mechanistic Study | NIH | National Institute on Drug Abuse | 2025 | $702,965 | June 15, 2025 | February 28, 2029 | YAMMINE, LUBA | reporter.nih.gov |
| Effect of Mindfulness Training on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment | NIH | National Center for Complementary & Integrative Health | 2022 | $700,000 | July 1, 2022 | August 31, 2024 | SCHUMAN OLIVIER, ZEV DAVID | reporter.nih.gov |
| Genetic Factors Underlying Risk for Methamphetamine Intake and Associated Traits | NIH | National Institute on Drug Abuse | 2021 to 2022 | $693,986 | September 30, 2018 | July 31, 2024 | PHILLIPS, TAMARA J. | reporter.nih.gov |
| Relevance and plasticity of inhibitory metabotropic signaling in reward circuits | NIH | National Institute on Drug Abuse | 2021 to 2022 | $688,500 | August 1, 2013 | February 28, 2023 | WICKMAN, KEVIN D | reporter.nih.gov |
| Applying a multiple methods approach to examine spatial and temporal variability in a state's illicit drug market | NIH | National Institute on Drug Abuse | 2025 | $688,271 | June 1, 2025 | February 28, 2030 | HEIMER, ROBERT | reporter.nih.gov |
| Combined mGluR5 PET and fMRI imaging of Sex Differences during Cocaine Withdrawal | NIH | National Institute on Drug Abuse | 2022 | $685,732 | June 1, 2017 | March 31, 2025 | MCCAUL, MARY E | reporter.nih.gov |
| Social Influences on Drug-Seeking Behavior | NIH | National Institute on Drug Abuse | 2021 to 2022 | $685,534 | April 1, 2012 | July 31, 2025 | SMITH, MARK A | reporter.nih.gov |
| Neuron subtype specific role of DNA methylcytosine dioxygenase TET1 in cocaine addiction | NIH | National Institute on Drug Abuse | 2021 to 2022 | $681,815 | September 15, 2018 | June 30, 2024 | FENG, JIAN | reporter.nih.gov |
| Defining molecular mechanisms by which stimulant evoked dopamine drives inflammation and neuronal dysfunction in neuroHIV | NIH | National Institute on Drug Abuse | 2025 | $677,147 | July 1, 2023 | June 30, 2028 | GASKILL, PETER JESSE | reporter.nih.gov |
| Neural Mechanisms underlying dissociable effects of cTBS in Psychostimulant Abuse | NIH | National Institute on Drug Abuse | 2025 | $674,709 | July 15, 2025 | April 30, 2030 | FROELIGER, BRETT | reporter.nih.gov |
| Screening and Brief Intervention for Prescription Stimulant Misuse and Diversion: Refining and Piloting a Curriculum for College Health Providers | NIH | National Institute on Drug Abuse | 2023 to 2025 | $672,656 | July 15, 2023 | May 31, 2027 | BAVARIAN, NILOOFAR | reporter.nih.gov |
| Development of selective cannabinoid receptor 2 agonists for treatment of addiction | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $661,980 | April 19, 2022 | March 31, 2023 | SHAMLOO, MEHRDAD | reporter.nih.gov |
| RESTORE (Recovery and Engagement for STimulant users On Re-entry) | NIH | National Institute on Drug Abuse | 2025 | $660,104 | August 15, 2025 | July 31, 2027 | NIJHAWAN, ANK ELISABETH | reporter.nih.gov |
| Estradiol signaling pathways mediating sex differences in striatal synaptic plasticity | NIH | National Institute on Drug Abuse | 2023 | $652,413 | April 15, 2023 | August 11, 2023 | BLACKWELL, KIM L | reporter.nih.gov |
| The Influence of Gonadal Hormones on Opioid Use | NIH | National Institute on Drug Abuse | 2021 to 2022 | $651,443 | September 30, 2018 | July 31, 2024 | SMITH, MARK A | reporter.nih.gov |
| The role of GPER-1 and addiction | NIH | National Institute on Drug Abuse | 2021 to 2022 | $649,193 | September 30, 2020 | July 31, 2024 | BECKER, JILL B. | reporter.nih.gov |
| Long-acting aldicarb hydrolase as a medical countermeasure for aldicarb poisoning | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $643,949 | September 1, 2023 | August 31, 2028 | ZHENG, FANG | reporter.nih.gov |
| Psilocybin-Assisted Treatment of Cocaine Use Disorder | NIH | National Institute on Drug Abuse | 2025 | $643,019 | July 15, 2025 | June 30, 2027 | ARIAS, ALBERT JOSEPH | reporter.nih.gov |
| Advancing Troriluzole as a Treatment for Methamphetamine Use Disorder: A Human Laboratory Study | NIH | National Institute on Drug Abuse | 2025 | $634,048 | April 15, 2025 | February 28, 2029 | STOOPS, WILLIAM WALTON | reporter.nih.gov |
| ADHD and Sleep: Evaluating the Impact of Drug-Drug and Drug-Disease Interactions to Inform Care | NIH | National Institute of Mental Health | 2025 | $633,671 | May 1, 2025 | February 28, 2030 | BUSHNELL, GRETA | reporter.nih.gov |
| Behavioral Safety and Fentanyl Education: BSAFE | NIH | National Institute on Drug Abuse | 2025 | $629,866 | September 30, 2025 | May 31, 2030 | COFFIN, PHILLIP O | reporter.nih.gov |
| HIV and Cocaine Use Leads to Loss of Astrocyte Neurotrophic Support and Impaired Lipid Homeostasis in the Brain | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $627,502 | September 20, 2022 | May 31, 2027 | LANGFORD, DIANNE TERESA | reporter.nih.gov |
| Targeting Immune Inflammation in Cocaine Use Disorder: A Human Laboratory Study with Pentoxifylline | NIH | National Institute on Drug Abuse | 2025 | $620,383 | July 1, 2025 | February 29, 2028 | STOOPS, WILLIAM WALTON | reporter.nih.gov |
| Data Mining and Functional Validation of SCORCH Datasets | NIH | National Institute on Drug Abuse | 2025 | $608,652 | September 1, 2025 | May 31, 2030 | SANNA, PIETRO P | reporter.nih.gov |
| Midcareer K24 Award for Mentoring and Patient-Oriented Research | NIH | National Institute on Drug Abuse | 2023 to 2025 | $602,500 | February 1, 2023 | January 31, 2028 | COFFIN, PHILLIP O | reporter.nih.gov |
| Modeling weekly and daily processes of a high-risk feedback cycle of alcohol, cannabis, and nonmedical use of prescription stimulants in college students: Impacts on use, academics, and sleep | NIH | National Institute on Drug Abuse | 2025 | $589,440 | May 15, 2025 | February 28, 2030 | FAIRLIE, ANNE MARIE | reporter.nih.gov |
| Norepinephrine modulates medial prefrontal cortex neural ensembles that control cocaine seeking behavior | NIH | National Institute on Drug Abuse | 2022 to 2025 | $586,321 | December 12, 2022 | May 31, 2027 | GHEIDI, ALI | reporter.nih.gov |
| Cell-Types Specific Neuroadaptations in the Nucleus Accumbens Shell Associated with Individual Differences in Cocaine-Seeking | NIH | National Institute on Drug Abuse | 2021 to 2023 | $580,446 | September 30, 2021 | September 2, 2023 | CARRERO, JEFFREY PARRILLA | reporter.nih.gov |
| Chromatin regulation of neuronal activity-induced enhancer priming and epigenetic memory | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $578,632 | March 1, 2025 | December 31, 2029 | WU, JIANG | reporter.nih.gov |
| Understanding the role of paraventricular neurotensin neurons in valence processing | NIH | National Institute on Drug Abuse | 2024 to 2025 | $577,653 | February 1, 2022 | January 31, 2027 | LI, HAO | reporter.nih.gov |
| Hybrid Trial of Peer-Supported Affect Regulation and Contingency Management to Improve HIV Prevention Outcomes in the Southern United States | NIH | National Institute on Drug Abuse | 2025 | $575,433 | August 1, 2025 | July 31, 2027 | LANCASTER, KATHRYN ELIZABETH | reporter.nih.gov |
| Cardiovascular, Immune and Psychosocial Benefits of Reduced Cocaine Use | NIH | National Institute on Drug Abuse | 2022 | $574,367 | September 1, 2017 | November 30, 2024 | STOOPS, WILLIAM WALTON | reporter.nih.gov |
| A Forward Genetic Screen to Identify Genes Involved in Amphetamine Action | NIH | National Institute on Drug Abuse | 2025 | $571,675 | May 15, 2025 | April 30, 2028 | CARVELLI, LUCIA | reporter.nih.gov |
| TASK ORDER 01 COCAINE INTERACTION SAFETY STUDIES IN RATS. TOXICOLOGICAL EVALUATIONS OF POTENTIAL MEDICATIONS IDIQ. ORDERING PERIOD: 09/12/2023 - 09/11/2024. NIDA REF. NO. N01DA-23-8939 | NIH | National Institute on Drug Abuse | 2023 | $571,190 | September 12, 2023 | September 11, 2024 | AROLFO , MARIA | reporter.nih.gov |
| HIV and Cocaine Drive Bone-Marrow Blood (BMB) Barrier Dysfunction and Altered Hematopoietic Stem Cell (HSC) Differentiation Leading to Cardiovascular Disease | NIH | National Institute on Drug Abuse | 2022 | $570,030 | April 1, 2022 | October 26, 2023 | ANDREWS, ALLISON MICHELLE | reporter.nih.gov |
| Leveraging Networks, Epidemiology, and Epidemic Modeling: Creative Approaches for HIV Elimination | NIH | National Institute on Drug Abuse | 2021 to 2023 | $568,491 | August 15, 2019 | July 31, 2025 | SKAATHUN, BRITT | reporter.nih.gov |
| Nucleus accumbens neuronal ensembles in drugs and natural rewards seeking. | NIH | National Institute on Drug Abuse | 2021 to 2023 | $564,842 | December 1, 2020 | August 16, 2023 | BATCHELDER, ABIGAIL | reporter.nih.gov |
| HIV and cocaine mediated lipid dysregulation in microglia: Immunometabolism mechanisms underlying NeuroHIV | NIH | National Institute on Drug Abuse | 2025 | $563,742 | July 15, 2025 | May 31, 2030 | GUO, MINGLEI | reporter.nih.gov |
| The role of neuronal ensemble Rac1 activity in cocaine seeking behavior | NIH | National Institute on Drug Abuse | 2024 | $563,694 | July 15, 2024 | April 30, 2025 | WARREN, BRANDON L | reporter.nih.gov |
| MRI data fusion to investigate effects of drug abuse on HIV neurological complications | NIH | National Institute on Drug Abuse | 2021 to 2022 | $556,750 | March 15, 2018 | June 30, 2023 | MEADE, CHRISTINA S | reporter.nih.gov |
| Mentoring clinician scientists in patient-oriented substance use disorder research | NIH | National Institute on Drug Abuse | 2023 to 2025 | $554,316 | June 15, 2023 | May 31, 2028 | SAKAI, JOSEPH T | reporter.nih.gov |
| Chemokine Receptor Antagonists (CRAs): Characterization in Preclinical Models of Methamphetamine Use Disorder | NIH | National Institute on Drug Abuse | 2025 | $552,629 | July 1, 2025 | March 31, 2030 | RAWLS, SCOTT M. | reporter.nih.gov |
| Identifying Electrophysiological Targets for Transcranial Magnetic Stimulation in Cocaine Use Disorder | NIH | National Institute on Drug Abuse | 2023 to 2025 | $547,813 | July 1, 2023 | June 30, 2028 | WEBBER, HEATHER E | reporter.nih.gov |
| The role of neuroactive steroids in stress, drug craving and drug use in cocaine use disorders | NIH | National Institute on Drug Abuse | 2021 to 2023 | $547,788 | February 1, 2019 | January 31, 2025 | MILIVOJEVIC, VERICA | reporter.nih.gov |
| Unhealthy alcohol use, other drug use, and mental health disorders: comorbidity burden in people with HIV, gaps in treatment, and impact on the HIV care continuum | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $535,104 | September 25, 2019 | August 31, 2025 | LESKO, CATHERINE | reporter.nih.gov |
| Impact of miRNAs on adult neurogenesis following exposure to methamphetamine and HIV-1 Infection | NIH | National Institute on Drug Abuse | 2024 to 2025 | $529,515 | April 1, 2024 | March 31, 2027 | PARK, MIN SEON | reporter.nih.gov |
| Local labor market contexts and substance use in young and middle adulthood: Using agent-based modeling to guide substance use prevention strategies | NIH | National Institute on Drug Abuse | 2023 to 2025 | $524,091 | July 1, 2023 | June 30, 2028 | OH, SEHUN | reporter.nih.gov |
| Defining the role of cortical circuit dynamics in learning and addiction | NIH | National Institute on Drug Abuse | 2021 to 2022 | $514,599 | March 1, 2020 | February 28, 2023 | SICILIANO, CODY | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Ut Southwestern Medical Center | Dallas, TX | 4 | $46.2 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 22 | $40.4 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 9 | $37 million | 0 | $0 |
| Intervexion Therapeutics, LLC | Little Rock, AR | 4 | $34.6 million | 0 | $0 |
| Yale University | New Haven, CT | 20 | $32.8 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 17 | $27.5 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 11 | $27.1 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 15 | $24.4 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 15 | $23.4 million | 0 | $0 |
| Clear Scientific, LLC | Cambridge, MA | 5 | $23.3 million | 0 | $0 |
| Hennepin Healthcare Research Institute | Minneapolis, MN | 1 | $22.4 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 21 | $21 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 8 | $19.8 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 3 | $19.5 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 19 | $19.4 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 12 | $19.4 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 15 | $19.3 million | 0 | $0 |
| Temple Univ of the Commonwealth | Philadelphia, PA | 14 | $17.6 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 15 | $17 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 8 | $16.9 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 13 | $16.3 million | 0 | $0 |
| Allen Institute | Seattle, WA | 1 | $14.5 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 16 | $14 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 8 | $13.9 million | 0 | $0 |
| University of Washington | Seattle, WA | 8 | $13.3 million | 0 | $0 |
| University of Florida | Gainesville, FL | 15 | $13 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 7 | $12.8 million | 0 | $0 |
| Broad Institute, Inc. | Cambridge, MA | 1 | $12.6 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 10 | $12.5 million | 0 | $0 |
| Jackson Laboratory | Bar Harbor, ME | 4 | $11.3 million | 0 | $0 |
| Emory University | Atlanta, GA | 7 | $11.1 million | 0 | $0 |
| Graduate School of Public Health and Health Policy | New York, NY | 3 | $10.8 million | 0 | $0 |
| Research Triangle Institute | Research Triangle Park, NC | 5 | $10.7 million | 0 | $0 |
| Florida International University | Miami, FL | 5 | $10.3 million | 0 | $0 |
| University of Chicago | Chicago, IL | 6 | $10.1 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 9 | $9.8 million | 0 | $0 |
| Phoenix Pharmalabs, Inc. | Woodscross, UT | 2 | $9 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 15 | $9 million | 0 | $0 |
| Ohio State University | Columbus, OH | 6 | $8.9 million | 0 | $0 |
| New York State Psychiatric Institute Dba Research Foundation for Mental Hygiene, INC | New York, NY | 7 | $8.6 million | 0 | $0 |
| Stanford University | Stanford, CA | 5 | $8.4 million | 0 | $0 |
| Mclean Hospital | Belmont, MA | 5 | $8.2 million | 0 | $0 |
| Drexel University | Philadelphia, PA | 11 | $7.7 million | 0 | $0 |
| Biocorrx Pharmaceuticals INC | Anaheim, CA | 1 | $7.4 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 8 | $7.3 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 7 | $7.2 million | 0 | $0 |
| Sparian Biosciences, Inc. | New York City, NY | 1 | $6.9 million | 0 | $0 |
| Rush University Medical Center | Chicago, IL | 4 | $6.9 million | 0 | $0 |
| Chestnut Health Systems, Inc. | Bloomington, IL | 4 | $6.8 million | 0 | $0 |
| Omeros Corporation | Seattle, WA | 1 | $6.7 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 2 | $6.6 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 5 | $6.5 million | 0 | $0 |
| Sanford Burnham Prebys Medical Discovery Institute | La Jolla, CA | 1 | $6.4 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 4 | $6.2 million | 0 | $0 |
| University of South Carolina at Columbia | Columbia, SC | 6 | $6.2 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 5 | $6.1 million | 0 | $0 |
| University of Mississippi Med CTR | Jackson, MS | 6 | $5.9 million | 0 | $0 |
| Duke University | Durham, NC | 7 | $5.8 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 6 | $5.8 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 16 | $5.7 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 6 | $5.6 million | 0 | $0 |
| Simon Fraser University | Burnaby | 1 | $5.3 million | 0 | $0 |
| Tempero Bio, Inc. | Oakland, CA | 1 | $5.3 million | 0 | $0 |
| Tonix Pharmaceuticals, Inc. | Chatham, NJ | 1 | $5.2 million | 0 | $0 |
| Public Health Foundation Enterprises | City Of Industry, CA | 4 | $5 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 3 | $4.9 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 2 | $4.8 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 3 | $4.7 million | 0 | $0 |
| Friends Research Institute, Inc. | Baltimore, MD | 3 | $4.7 million | 0 | $0 |
| Myosin Therapeutics Inc. | Jupiter, FL | 2 | $4.7 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 5 | $4.7 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 7 | $4.6 million | 0 | $0 |
| Brown University | Providence, RI | 3 | $4.5 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 5 | $4.5 million | 0 | $0 |
| Public Health Institute | Oakland, CA | 2 | $4.4 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 5 | $4.2 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 3 | $4.1 million | 0 | $0 |
| University of California-Riverside | Riverside, CA | 3 | $4.1 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 3 | $4.1 million | 0 | $0 |
| University of Rochester | Rochester, NY | 2 | $3.9 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 5 | $3.8 million | 0 | $0 |
| Florida State University | Tallahassee, FL | 3 | $3.8 million | 0 | $0 |
| Virogenomics Biodevelopment, Inc. | Tigard, OR | 2 | $3.7 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 1 | $3.7 million | 0 | $0 |
| University of Texas at Austin | Austin, TX | 4 | $3.6 million | 0 | $0 |
| University of Connecticut | Storrs, CT | 4 | $3.5 million | 0 | $0 |
| Lovelace Biomedical Research Institute | Albuquerque, NM | 2 | $3.5 million | 0 | $0 |
| Southern Research Institute | Birmingham, AL | 1 | $3.4 million | 0 | $0 |
| University of California-Santa Barbara | Santa Barbara, CA | 3 | $3.3 million | 0 | $0 |
| San Diego Biomedical Research Institute | San Diego, CA | 3 | $3.3 million | 0 | $0 |
| Trustees of Boston University | Boston, MA | 2 | $3.2 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 2 | $3 million | 0 | $0 |
| Meharry Medical College | Nashville, TN | 1 | $3 million | 0 | $0 |
| Evon Medics, LLC | Elkridge, MD | 1 | $2.9 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 1 | $2.9 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 4 | $2.9 million | 0 | $0 |
| Virginia Polytechnic Institute and State University | Blacksburg, VA | 1 | $2.8 million | 0 | $0 |
| Praeventix, LLC | Exton, PA | 1 | $2.8 million | 0 | $0 |
| University of Toledo Health Sci Campus | Toledo, OH | 2 | $2.8 million | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 1 | $2.8 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 394 | $253,881,577 | 0 | $0 |
| 2024 | 402 | $231,273,523 | 0 | $0 |
| 2023 | 404 | $232,190,984 | 0 | $0 |
| 2022 | 419 | $263,494,892 | 0 | $0 |
| 2021 | 272 | $177,524,298 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.